| | |
页数
|
| |||
关于本招股说明书
|
| | | | 1 | | |
财务报表列报
|
| | | | 2 | | |
行业和市场数据
|
| | | | 3 | | |
常用术语
|
| | | | 4 | | |
前瞻性声明
|
| | | | 6 | | |
招股说明书摘要
|
| | | | 8 | | |
产品
|
| | | | 16 | | |
风险因素
|
| | | | 17 | | |
大写 | | | | | 86 | | |
YS BioPharma历史财务数据精选
|
| | | | 87 | | |
使用收益
|
| | | | 90 | | |
股利政策
|
| | | | 91 | | |
市场机会
|
| | | | 92 | | |
业务 | | | | | 107 | | |
管理层讨论、财务状况和运营结果
|
| | | | 191 | | |
管理 | | | | | 215 | | |
慈善机构的所有权
|
| | | | 224 | | |
销售企业持有人
|
| | | | 226 | | |
某些关系和关联人交易
|
| | | | 229 | | |
我们的业务描述
|
| | | | 231 | | |
有资格未来出售的股票
|
| | | | 236 | | |
税务 | | | | | 238 | | |
配送计划
|
| | | | 247 | | |
与发行有关的费用
|
| | | | 251 | | |
法律事务
|
| | | | 252 | | |
专家 | | | | | 253 | | |
您可以在哪里找到更多信息
|
| | | | 256 | | |
财务报表索引
|
| | | | F-1 | | |
| | |
截至2022年9月30日
|
| |||||||||
| | |
实际
|
| |
调整后的
|
| ||||||
| | |
美元
|
| |
美元
|
| ||||||
现金和现金等价物
|
| | | | 31,976,572 | | | | | | 76,884,343 | | |
总负债
|
| | | | 125,434,750 | | | | | | 130,942,677 | | |
股权 | | | | | | | | | | | | | |
普通股
|
| | | | 1,124 | | | | | | 1,968 | | |
实际缴费人均增加
|
| | | | 113,897,365 | | | | | | 392,263,188 | | |
累计亏损
|
| | | | (235,749,706) | | | | | | (247,933,610) | | |
累计其他综合收益(亏损)
|
| | | | (12,051,884) | | | | | | (12,051,887) | | |
总股本
|
| | | | (133,903,101) | | | | | | 132,279,659 | | |
资本总额
|
| | | | (8,468,351) | | | | | | 263,222,336 | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | |||||||||
收入 | | | | | 269,433,426 | | | | | | 399,534,723 | | | | | | $56,274,081 | | | | | | 257,015,929 | | | | | | 502,949,894 | | | | | | $ 79,227,166 | | |
收入成本
|
| | | | 63,599,621 | | | | | | 93,700,779 | | | | | | 13,197,665 | | | | | | 59,656,877 | | | | | | 117,066,090 | | | | | | 18,440,832 | | |
毛利
|
| | | | 205,833,805 | | | | | | 305,833,944 | | | | | | 43,076,416 | | | | | | 197,359,052 | | | | | | 385,883,804 | | | | | | 60,786,334 | | |
运营费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | 86,265,281 | | | | | | 150,228,079 | | | | | | 21,159,480 | | | | | | 73,485,259 | | | | | | 185,999,704 | | | | | | 29,299,597 | | |
一般和行政
|
| | | | 51,664,591 | | | | | | 49,587,013 | | | | | | 6,984,283 | | | | | | 155,334,386 | | | | | | 107,620,500 | | | | | | 16,952,916 | | |
研发
|
| | | | 124,051,209 | | | | | | 123,861,107 | | | | | | 17,445,718 | | | | | | 94,387,144 | | | | | | 211,222,263 | | | | | | 33,272,780 | | |
总运营费用
|
| | | | 261,981,081 | | | | | | 323,676,199 | | | | | | 45,589,481 | | | | | | 323,206,789 | | | | | | 504,842,467 | | | | | | 79,525,293 | | |
运营亏损
|
| | | | (56,147,276) | | | | | | (17,842,255) | | | | | | (2,513,065) | | | | | | (125,847,737) | | | | | | (118,958,663) | | | | | | (18,738,959) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
所得税相关滞纳金
|
| | | | (112,420) | | | | | | — | | | | | | — | | | | | | (11,464,741) | | | | | | — | | | | | | — | | |
与所得税以外的税种相关的滞纳金
|
| | | | (1,396,221) | | | | | | (299,417) | | | | | | (42,173) | | | | | | (7,261,947) | | | | | | (231,231) | | | | | | (36,425) | | |
与社保相关的滞纳金
|
| | | | — | | | | | | — | | | | | | — | | | | | | (7,701,793) | | | | | | (1,852,378) | | | | | | (291,796) | | |
政府拨款
|
| | | | 19,600,822 | | | | | | 22,456,691 | | | | | | 3,163,003 | | | | | | 3,530,405 | | | | | | 23,020,413 | | | | | | 3,626,290 | | |
财务费用,净额
|
| | | | (352,694) | | | | | | (14,949,434) | | | | | | (2,105,613) | | | | | | (29,689,927) | | | | | | (2,717,433) | | | | | | (428,064) | | |
其他收入(支出),净额
|
| | | | (993,957) | | | | | | 74,675 | | | | | | 10,518 | | | | | | 4,063,743 | | | | | | (327,987) | | | | | | (51,666) | | |
其他(费用)收入总额,
净额 |
| | | | 16,745,530 | | | | | | 7,282,515 | | | | | | 1,025,735 | | | | | | (48,524,260) | | | | | | 17,891,384 | | | | | | 2,818,339 | | |
所得税前亏损
|
| | | | (39,401,746) | | | | | | (10,559,740) | | | | | | (1,487,330) | | | | | | (174,371,997) | | | | | | (101,067,279) | | | | | | (15,920,620) | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | |||||||||
所得税费用
|
| | | | (5,689,586) | | | | | | (565,625) | | | | | | (79,668) | | | | | | (17,454,245) | | | | | | (4,937,122) | | | | | | (777,720) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | | | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (65,013,751) | | | | | | (72,083,238) | | | | | | (10,152,855) | | | | |
|
(16,610,297)
|
| | | | | (130,662,326) | | | | |
|
(20,582,579)
|
| |
应占YS Bianjima Co. Ltd的净亏损
|
| | | | (110,105,083) | | | | | | (83,208,603) | | | | | | $(11,719,853) | | | | | | (208,436,539) | | | | | | (236,666,727) | | | | | | $(37,280,919) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | $ (1,566,998) | | | | | | (191,826,242) | | | | | | (106,004,401) | | | | | | $(16,698,340) | | |
其他综合收益:外币换算收益
|
| | | | 11,321,167 | | | | | | (168,653,952) | | | | | | (23,754,747) | | | | | | 22,455,217 | | | | | | 38,864,606 | | | | | | 6,122,146 | | |
全面亏损
|
| | | | (33,770,165) | | | | | | (179,779,317) | | | | | | $(25,321,745) | | | | | | (169,371,025) | | | | | | (67,139,795) | | | | | | $(10,576,194) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.18) | | | | | | (0.05) | | | | | | $ (0.01) | | | | | | (0.78) | | | | | | (0.43) | | | | | | $ (0.07) | | |
已发行普通股加权平均数*:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,141,861 | | | | | | 247,141,861 | | | | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
|
| | |
截至9月30日
|
| |
截至3月31日
|
| ||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | ||||||
资产 | | | | | | | | | | | | | | | | | | | | | | ||||||||||
流动资产
|
| | | | 871,552,683 | | | | | | 122,757,357 | | | | | | 733,204,286 | | | | | | 764,764,393 | | | | | | 120,469,486 | | |
非流动资产合计
|
| | | | 676,885,437 | | | | | | 95,338,663 | | | | | | 433,970,786 | | | | | | 676,988,748 | | | | | | 106,642,631 | | |
总资产
|
| | | | 1,548,438,120 | | | | | | $ 218,096,020 | | | | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | | $ 227,112,117 | | |
负债、夹层股权和股东亏损
|
| | | | | | | | | | | | | | | | | | | | | ||||||||||
流动负债
|
| | | | 575,338,836 | | | | | | 81,035,921 | | | | | | 345,040,994 | | | | | | 475,914,160 | | | | | | 74,968,363 | | |
非流动负债
|
| | | | 315,222,809 | | | | | | 44,398,829 | | | | | | 45,538,214 | | | | | | 294,586,777 | | | | | | 46,404,772 | | |
总负债
|
| | | | 890,561,645 | | | | | | 125,434,750 | | | | | | 390,579,208 | | | | | | 770,500,937 | | | | | | 121,373,135 | | |
夹层股权
|
| | | | 1,608,561,727 | | | | | | 226,564,371 | | | | | | 1,285,458,571 | | | | | | 1,370,221,392 | | | | | | 215,844,081 | | |
股东亏损
|
| | | | (950,685,252) | | | | | | (133,903,101) | | | | | | (508,862,707) | | | | | | (698,969,188) | | | | | | (110,105,099) | | |
总负债、夹层权益和股东亏损
|
| | | | 1,548,438,120 | | | | | | $ 218,096,020 | | | | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | | $ 227,112,117 | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | |||||||||
经营活动使用的现金净额
|
| | | | (176,984,374) | | | | | | (107,395,153) | | | | | | (15,126,504) | | | | | | (246,610,437) | | | | | | (173,545,357) | | | | | | (27,337,727) | | |
投资活动中使用的净现金:
|
| | | | (203,390,377) | | | | | | (19,024,351) | | | | | | (2,679,561) | | | | | | (104,238,941) | | | | | | (298,923,958) | | | | | | (47,087,987) | | |
融资活动提供的净现金:
|
| | | | 43,885,865 | | | | | | 51,907,325 | | | | | | 7,311,097 | | | | | | 739,258,696 | | | | | | 364,558,145 | | | | | | 57,427,010 | | |
汇率对汇率的影响
现金储备 |
| | | | (4,446,301) | | | | | | 30,471,942 | | | | | | 4,291,943 | | | | | | (2,674) | | | | | | (11,478,411) | | | | | | (1,808,136) | | |
现金净增(减)
|
| | | | (340,935,187) | | | | | | (44,040,237) | | | | | | (6,203,025) | | | | | | 388,406,644 | | | | | | (119,389,581) | | | | | | (18,806,840) | | |
会计年度开始时的现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | | 38,179,597 | | | | | | 2,050,440 | | | | | | 390,457,084 | | | | | | 61,506,740 | | |
财政年度末现金
|
| | | | 49,521,897 | | | | | | 227,027,266 | | | | | | $ 31,976,572 | | | | | | 390,457,084 | | | | | | 271,067,503 | | | | | | $ 42,699,900 | | |
排名
|
| |
疫苗
|
| |
数量:
批次发放 |
| |||
1
|
| |
狂犬病疫苗
|
| | | | 983 | | |
2
|
| |
乙肝疫苗
|
| | | | 565 | | |
3
|
| |
脑膜炎疫苗
|
| | | | 563 | | |
4
|
| |
流感疫苗(含HIB)
|
| | | | 553 | | |
5
|
| |
水痘疫苗
|
| | | | 471 | | |
6
|
| |
脊髓灰质炎疫苗
|
| | | | 339 | | |
7
|
| |
MMR疫苗
|
| | | | 281 | | |
8
|
| |
HPV疫苗
|
| | | | 254 | | |
9
|
| |
流行性乙型脑炎疫苗
|
| | | | 224 | | |
10
|
| |
百白破疫苗
|
| | | | 203 | | |
年
|
| |
2012
|
| |
2013
|
| |
2014
|
| |
2015
|
| |
2016
|
| |
2017
|
| |
2018
|
| |
2019
|
| |
2020
|
| |
2021
|
| ||||||||||||||||||||||||||||||
批次释放(百万剂)
|
| | | | 126.2 | | | | | | 73.3 | | | | | | 58.8 | | | | | | 77.8 | | | | | | 58.9 | | | | | | 78.2 | | | | | | 62.9 | | | | | | 58.8 | | | | | | 78.6 | | | | | | 88.0 | | |
系统机构类(SOC)
|
| |
首选术语(PT)
|
| |
拉比普尔
N=12 |
| |
鼠兔狂犬病
疫苗 (1-1-1-1) N=13 |
| |
鼠兔狂犬病
疫苗 (2-2-1) N=12 |
|
| | | | | |
(单位n(%))
|
| |
(单位n(%))
|
| |
(单位n(%))
|
|
胃肠道疾病
|
| | 腹泻 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
| | | 恶心 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
全身疾病和用药部位情况
|
| | 硬化 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
0 (0.00%)
|
|
| | | 疲劳 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
0 (0.00%)
|
|
| | | 注射部位疼痛 | | |
0 (0.00%)
|
| |
6 (46.15%)
|
| |
3 (25.00%)
|
|
| | |
注射部位肿胀
|
| |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 发热 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
感染和侵扰
|
| |
淋巴腺感染
|
| |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
0 (0.00%)
|
|
| | | 脓尿 | | |
0 (0.00%)
|
| |
2 (15.38%)
|
| |
1 (8.33%)
|
|
调查
|
| |
存在葡萄糖尿
|
| |
0 (0.00%)
|
| |
2 (15.38%)
|
| |
0 (0.00%)
|
|
肌肉骨骼和结缔组织
障碍 |
| | 肌痛 | | |
0 (0.00%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
神经系统疾病
|
| | 头晕 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 头痛 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
1 (8.33%)
|
|
| | | 昏昏欲睡 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
肾脏和泌尿系疾病
|
| | 蛋白尿 | | |
0 (0.00%)
|
| |
2 (15.38%)
|
| |
0 (0.00%)
|
|
系统机构类(SOC)
|
| |
首选术语(PT)
|
| |
拉比普尔
N=12 |
| |
鼠兔狂犬病
疫苗 (1-1-1-1) N=13 |
| |
鼠兔狂犬病
疫苗 (2-2-1) N=12 |
|
| | | | | |
(单位n(%))
|
| |
(单位n(%))
|
| |
(单位n(%))
|
|
呼吸系统、胸腔和纵隔
障碍 |
| | 咳嗽 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
皮肤和皮下组织疾病
|
| | 多汗症 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 瘙痒症 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 荨麻疹 | | |
0 (0.00%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
至少有一次不良事件的受试者总数
|
| | | | |
5 (41.67%)
|
| |
9 (69.23%)
|
| |
6 (50.00%)
|
|
| | |
拉比普尔
|
| |
鼠兔狂犬病
疫苗(1-1-1-1) |
| |
鼠兔狂犬病
疫苗(2-2-1) |
|
| | |
平均值±标准差
95%可信区间 |
| |
平均值±标准差
95%可信区间 |
| |
平均值±标准差
95%可信区间 |
|
中和
|
| |
9.72 ± 11.66
|
| |
12.07 ± 10.07
|
| |
20.06 ± 33.12
|
|
抗体效价
|
| |
(-2.67, 22.11)
|
| |
(-0.31, 24.46)
|
| |
(8.26, 33.04)
|
|
| | |
拉比普尔
|
| |
鼠兔狂犬病
疫苗(2-2-1) |
|
| | |
平均值±标准差
95%可信区间 |
| |
平均值±标准差
95%可信区间 |
|
中和抗体效价
|
| |
19.16 ± 13.53
|
| |
21.59 ± 46.90
|
|
| | |
(15.69, 22.62)
|
| |
(9.15, 34.04)
|
|
世卫组织标签
|
| |
Pango
血统 |
| |
GISAID
支系/世系 |
| |
下一个菌株
分支 |
| |
最早记录的样本
|
| |
日期:
称号 |
|
| | |
VOCs(1)
|
| | |||||||||||
Alpha
|
| |
B.1.1.7
|
| |
GRY(前身为
GR/501Y.V1) |
| |
20i(V1)
|
| |
英国,2020年9月
|
| |
2020年12月18日
|
|
测试版
|
| |
B.1.351
|
| |
GH/501Y.V2
|
| |
20H(V2)
|
| |
南非,2020年5月
|
| |
2020年12月18日
|
|
伽马
|
| |
P.1
|
| |
GR/501Y.V3
|
| |
20J(V3)
|
| |
巴西,2020年11月
|
| |
2021年1月11日
|
|
Delta
|
| |
B.1.617.2
|
| |
G/478K.V1
|
| |
21A
|
| |
印度,2020年10月
|
| |
VOI:2021年4月4日
VOC:2021年5月11日 |
|
| | | | | | | | |
vois(2)
|
| | | | | | |
Epsilon
|
| |
B.1.427/B.1.429
|
| |
GH/452R.V1
|
| |
21C
|
| |
美国,2020年3月
|
| |
2021年3月5日
|
|
泽塔
|
| |
P.2
|
| |
GR/484K.V2
|
| |
20B
|
| |
巴西,2020年4月
|
| |
2021年3月17日
|
|
埃塔
|
| |
B.1.525
|
| |
G/484K.V3
|
| |
21D
|
| |
多个国家,2020年12月
|
| |
2021年3月17日
|
|
Theta
|
| |
P.3
|
| |
GR/1092K.V1
|
| |
21E
|
| |
菲律宾,2021年1月
|
| |
2021年3月24日
|
|
IOTA
|
| |
B.1.526
|
| |
GH/253G.V1
|
| |
21F
|
| |
美国,2020年11月
|
| |
2021年3月24日
|
|
卡帕
|
| |
B.1.617.1
|
| |
G/452R.V3
|
| |
21B
|
| |
印度,2020年10月
|
| |
2021年4月4日
|
|
Lambda
|
| |
C.37
|
| |
GR/452Q.V1
|
| |
20D
|
| |
秘鲁,2020年8月
|
| |
2021年6月14日
|
|
参观(天)
|
| |
血清转换率(%)
低剂量 乙肝病毒-001 |
| |
高剂量
乙肝病毒-001 |
| |
Engerix-B
|
| |||||||||
基线
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
D 56
|
| | | | 87.5 | | | | | | 100 | | | | | | 66.7 | | |
D 84
|
| | | | 90 | | | | | | 100 | | | | | | 66.7 | | |
D 196
|
| | | | 90 | | | | | | 100 | | | | | | 88.9 | | |
动物模型
|
| |
代理
|
| |
T/C(%)
|
| |
IR(%)
|
| ||||||
乳腺癌4T1原位模型
|
| | 鼠兔YS-On-001 | | | | | 45.87 | | | | | | 42.26 | | |
| | | 多西紫杉醇 | | | | | 50.12 | | | | | | 35.55 | | |
Lewis肺癌LL/2移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 37.02 | | | | | | 60.88 | | |
| | | 顺铂鼠兔 | | | | | 47.46 | | | | | | 42.38 | | |
| | | YS-On-001+顺铂 | | | | | 28.38 | | | | | | 75.44 | | |
肝癌H22移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 18.84 | | | | | | 73.40 | | |
| | | Sorafenib Pika | | | | | 36.79 | | | | | | 53.73 | | |
| | | YS-On-001+索拉非尼 | | | | | 12.56 | | | | | | 88.19 | | |
结肠癌CT-26移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 5.38 | | | | | | 97.71 | | |
| | | PD-1 | | | | | 53.66 | | | | | | 47.05 | | |
前列腺癌RM-1移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 1.39 | | | | | | 98.56 | | |
| | | PD-1 | | | | | 57.62 | | | | | | 38.12 | | |
黑色素瘤B16-F10转移瘤模型 | | | | | | | | | | | | | | | | |
产品/技术
|
| |
专利名称
|
| |
所有者/申请人
|
| |
管辖权
|
| |
专利状态(1)
|
| |
专利到期
|
| |
专利类型
|
|
鼠兔佐剂
|
| |
聚肌苷-多胞苷酸佐剂
|
| |
新加坡益生
|
| |
澳大利亚、巴西、加拿大、古巴、欧盟、奥地利、比利时、瑞士、丹麦、法国、英国、爱尔兰、意大利、荷兰、波兰、土耳其、西班牙、瑞典、德国、印度尼西亚、以色列、印度、韩国、马来西亚、新西兰、菲律宾、俄罗斯、新加坡、泰国、台湾(中国)、美国、越南、南非
|
| |
已批准
|
| |
2025年至2027年
|
| |
物质的组成
|
|
|
新加坡益生
|
| | 美国、墨西哥 | | | 已批准 | | | 2025 | | | | | |||||
|
含有多肌苷酸-多胞苷酸佐剂的免疫原性物质
|
| |
新加坡益生
|
| |
中国、澳大利亚、香港、古巴、印度尼西亚、印度、墨西哥、马来西亚、新西兰、菲律宾、俄罗斯、新加坡、台湾(中国)、美国、越南、南非
|
| |
已批准
|
| |
2026至2028
|
| |
物质的组成
|
| ||
|
新加坡益生
|
| | 巴西、泰国 | | | 待定 | | | 不适用 | | | |||||||
|
含有多肌苷酸-多胞苷酸佐剂的粘膜免疫原性物质
|
| |
新加坡益生
|
| |
澳大利亚、加拿大、香港、古巴、印度尼西亚、韩国、马来西亚、新西兰、菲律宾、新加坡、南非
|
| |
已批准
|
| |
2026至2028
|
| |
物质的组成
|
| ||
| 北京益生 | | | 中国 | | | 已批准 | | | 2026 | | | |||||||
|
新加坡益生
|
| | 台湾(中国) | | | 已批准 | | | 2027 | | | |||||||
|
新加坡益生
|
| | 泰国、巴西 | | | 待定 | | | 不适用 | | | |||||||
鼠兔狂犬病疫苗(Vero细胞)
|
| |
一种含有鼠兔佐剂的狂犬病组合物
|
| |
新加坡益生
|
| |
中国、印度尼西亚、俄罗斯、南非
|
| |
已批准
|
| |
2034至2037
|
| |
物质的组成
|
|
|
新加坡益生
|
| |
巴西、印度、菲律宾、泰国、美国、越南
|
| | 待定 | | | 不适用 | | | |||||||
鼠兔YS-On-001(癌症)
|
| |
一种含有PIC的组合物,用于治疗癌症
|
| |
新加坡益生
|
| |
美国、欧盟、俄罗斯、南非
|
| |
已批准
|
| |
2037至2038
|
| |
物质的组成
|
|
|
新加坡益生
|
| |
澳大利亚、巴西、加拿大、香港、古巴、印度尼西亚、印度、韩国、墨西哥、马来西亚、新西兰、菲律宾、新加坡、泰国、美国、越南
|
| | 待定 | | | 不适用 | | |
项目
|
| |
施工
区域 |
| |
实际/预期
施工 开工 日期 |
| |
预期为
施工 完工日期 |
| |
预期为
制造 容量 |
|
| | |
(平方米)
|
| | | | | | | |
(总数为
剂量/年) |
|
新加坡一家鼠兔狂犬病疫苗生产车间 | | | 14,577 | | | 2023年10月 | | | 2025年3月 | | | 待定 | |
沈阳两家鼠疫重组新冠肺炎疫苗生产车间(中国) | | | 6,831 | | | 2021年3月 | | | 2023年3月 | | | 5亿 | |
产品
|
| |
许可证/许可证
|
| |
许可证/许可证
托架 |
| |
权威机构
|
| |
有效期
期间 |
|
YSJATM狂犬病疫苗 | | |
药品重新注册证书
|
| |
辽宁益生
|
| |
辽宁省医疗产品管理局
|
| |
2020.07.13 – 2025.07.12
|
|
YSJATM狂犬病疫苗/鼠兔重组COVID19疫苗 | | |
药品生产许可证
|
| |
辽宁益生
|
| |
辽宁省医疗产品管理局
|
| |
2022.06.15 – 2024.08.14
|
|
| | |
截至2022年9月30日
|
| |||||||||
函数
|
| |
数量:
员工 |
| |
占总数的%
|
| ||||||
研发
|
| | | | 206 | | | | | | 23.82 | | |
一般和行政
|
| | | | 172 | | | | | | 19.88 | | |
制造
|
| | | | 436 | | | | | | 50.40 | | |
销售、市场营销和患者服务
|
| | | | 51 | | | | | | 5.90 | | |
合计 | | | | | 865 | | | | | | 100 | | |
| | |
截至9月30日的6个月
|
| |
截至3月31日的财政年度
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |
2022
|
| |
2021
|
| |
差异
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
人民币
|
| |
$
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
$
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||||||||||||||||||||||||||
收入
|
| | | | 399,534,723 | | | | | | 56,274,081 | | | | | | 100.0 | | | | | | 269,433,426 | | | | | | 100.0 | | | | | | 130,101,297 | | | | | | 48.3 | | | | | | 502,949,894 | | | | | | 79,227,166 | | | | | | 100.0 | | | | | | 257,015,929 | | | | | | 100.0 | | | | | | 245,933,965 | | | | | | 95.7 | | |
收入成本
|
| | | | 93,700,779 | | | | | | 13,197,665 | | | | | | 100.0 | | | | | | 63,599,621 | | | | | | 100.0 | | | | | | 30,101,158 | | | | | | 47.3 | | | | | | 117,066,090 | | | | | | 18,440,832 | | | | | | 100.0 | | | | | | 59,656,877 | | | | | | 100.0 | | | | | | 57,409,213 | | | | | | 96.2 | | |
毛利
|
| | | | 305,833,944 | | | | | | 43,076,416 | | | | | | 76.5 | | | | | | 205,833,805 | | | | | | 76.4 | | | | | | 100,000,139 | | | | | | 48.6 | | | | | | 385,883,804 | | | | | | 60,786,334 | | | | | | 76.7 | | | | | | 197,359,052 | | | | | | 76.8 | | | | | | 188,524,752 | | | | | | 95.5 | | |
运营费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||
销售费用
|
| | | | 150,228,079 | | | | | | 21,159,480 | | | | | | 46.4 | | | | | | 86,265,281 | | | | | | 32.9 | | | | | | 63,962,798 | | | | | | 74.1 | | | | | | 185,999,704 | | | | | | 29,299,597 | | | | | | 36.8 | | | | | | 73,485,259 | | | | | | 22.7 | | | | | | 112,514,445 | | | | | | 153.1 | | |
一般和行政
费用 |
| | | | 49,587,013 | | | | | | 6,984,283 | | | | | | 15.3 | | | | | | 51,664,591 | | | | | | 19.7 | | | | | | (2,077,578) | | | | | | (4.0) | | | | | | 107,620,500 | | | | | | 16,952,916 | | | | | | 21.3 | | | | | | 155,334,386 | | | | | | 48.1 | | | | | | (47,713,886) | | | | | | (30.7) | | |
研发费用
|
| | | | 123,861,107 | | | | | | 17,445,718 | | | | | | 38.3 | | | | | | 124,051,209 | | | | | | 47.4 | | | | | | (190,102) | | | | | | (0.2) | | | | | | 211,222,263 | | | | | | 33,272,780 | | | | | | 41.9 | | | | | | 94,387,144 | | | | | | 29.2 | | | | | | 116,835,119 | | | | | | 123.8 | | |
总运营费用
|
| | | | 323,676,199 | | | | | | 45,589,481 | | | | | | 100.0 | | | | | | 261,981,081 | | | | | | 100.0 | | | | | | 61,695,118 | | | | | | 23.5 | | | | | | 504,842,467 | | | | | | 79,525,293 | | | | | | 100.0 | | | | | | 323,206,789 | | | | | | 100.0 | | | | | | 181,635,678 | | | | | | 56.2 | | |
运营亏损
|
| | | | (17,842,255) | | | | | | (2,513,065) | | | | | | (4.5) | | | | | | (56,147,276) | | | | | | (20.8) | | | | | | 38,305,021 | | | | | | (68.2) | | | | | | (118,958,663) | | | | | | (18,738,959) | | | | | | (23.7) | | | | | | (125,847,737) | | | | | | (49.0) | | | | | | 6,889,074 | | | | | | (5.5) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||
与
相关的滞纳金
所得税 |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (11,464,741) | | | | | | 23.6 | | | | | | 11,464,741 | | | | | | (100.0) | | |
与所得税以外的其他税收有关的滞纳金
税 |
| | | | — | | | | | | — | | | | | | — | | | | | | (112,420) | | | | | | (0.7) | | | | | | 112,420 | | | | | | (100.0) | | | | | | (231,231) | | | | | | (36,425) | | | | | | (1.3) | | | | | | (7,261,947) | | | | | | 15.0 | | | | | | 7,030,716 | | | | | | (96.8) | | |
社会保险相关滞纳金
|
| | | | (299,417) | | | | | | (42,173) | | | | | | (4.1) | | | | | | (1,396,221) | | | | | | (8.3) | | | | | | 1,096,804 | | | | | | (78.6) | | | | | | (1,852,378) | | | | | | (291,796) | | | | | | (10.4) | | | | | | (7,701,793) | | | | | | 15.9 | | | | | | 5,849,415 | | | | | | (75.9) | | |
政府拨款
|
| | | | 22,456,691 | | | | | | 3,163,003 | | | | | | 308.4 | | | | | | 19,600,822 | | | | | | 117.1 | | | | | | 2,855,869 | | | | | | 14.6 | | | | | | 23,020,413 | | | | | | 3,626,290 | | | | | | 128.7 | | | | | | 3,530,405 | | | | | | (7.3) | | | | | | 19,490,008 | | | | | | 552.1 | | |
财务费用净额
|
| | | | (14,949,434) | | | | | | (2,105,613) | | | | | | (205.3) | | | | | | (352,694) | | | | | | (2.2) | | | | | | (14,596,740) | | | | | | 4,138.6 | | | | | | (2,717,433) | | | | | | (428,064) | | | | | | (15.2) | | | | | | (29,689,927) | | | | | | 61.2 | | | | | | 26,972,494 | | | | | | (90.8) | | |
其他收入,净额
|
| | | | 74,675 | | | | | | 10,518 | | | | | | 1.0 | | | | | | (993,957) | | | | | | (5.9) | | | | | | 1,068,632 | | | | | | (107.5) | | | | | | (327,987) | | | | | | (51,666) | | | | | | (1.8) | | | | | | 4,063,743 | | | | | | (8.4) | | | | | | (4,391,730) | | | | | | (108.1) | | |
其他收入总额,净额
|
| | | | 7,282,515 | | | | | | 1,025,735 | | | | | | 100.0 | | | | | | 16,745,530 | | | | | | 100.0 | | | | | | (9,463,015) | | | | | | (56.5) | | | | | | 17,891,384 | | | | | | 2,818,339 | | | | | | 100.0 | | | | | | (48,524,260) | | | | | | 100.0 | | | | | | 66,415,644 | | | | | | (136.9) | | |
所得税前亏损
|
| | | | (10,559,740) | | | | | | (1,487,330) | | | | | | (2.6) | | | | | | (39,401,746) | | | | | | (14.6) | | | | | | 28,842,006 | | | | | | (73.2) | | | | | | (101,067,279) | | | | | | (15,920,620) | | | | | | (20.1) | | | | | | (174,371,997) | | | | | | (67.8) | | | | | | 73,304,718 | | | | | | (42.0) | | |
收入拨备
税费 |
| | | | (565,625) | | | | | | (79,668) | | | | | | (0.1) | | | | | | (5,689,586) | | | | | | (2.1) | | | | | | 5,123,961 | | | | | | (90.1) | | | | | | (4,937,122) | | | | | | (777,720) | | | | | | (1.0) | | | | | | (17,454,245) | | | | | | (6.8) | | | | | | 12,517,123 | | | | | | (71.7) | | |
净亏损
|
| | | | (11,125,365) | | | | | | (1,566,998) | | | | | | (2.7) | | | | | | (45,091,332) | | | | | | (16.7) | | | | | | 33,965,967 | | | | | | (75.3) | | | | | | (106,004,401) | | | | | | (16,698,340) | | | | | | (21.1) | | | | | | (191,826,242) | | | | | | (74.6) | | | | | | 85,821,841 | | | | | | (44.7) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
推广和营销服务费
|
| | | | 138,166,922 | | | | | | 92.0 | | | | | | 77,896,957 | | | | | | 90.3 | | | | | | 60,269,965 | | | | | | 77.4 | | |
员工福利支出
|
| | | | 11,086,976 | | | | | | 7.4 | | | | | | 7,426,168 | | | | | | 8.6 | | | | | | 3,660,808 | | | | | | 49.3 | | |
其他
|
| | | | 974,181 | | | | | | 0.6 | | | | | | 942,156 | | | | | | 1.1 | | | | | | 32,025 | | | | | | 3.4 | | |
合计
|
| | | | 150,228,079 | | | | | | 100 | | | | | | 86,265,281 | | | | | | 100 | | | | | | 63,962,798 | | | | | | 74.1 | | |
截至9月30日的6个月
|
| |
0 - 90天
|
| |
90 - 180天
|
| |
180 - 365天
|
| |
>365天
|
| |
合计
|
| |||||||||||||||
2022(人民币)
|
| | | | 45,909,832 | | | | | | 50,517,783 | | | | | | 29,990,148 | | | | | | 11,328,780 | | | | | | 137,746,543 | | |
2022(美元)
|
| | | $ | 6,466,356 | | | | | $ | 7,115,381 | | | | | $ | 4,224,083 | | | | | $ | 1,595,648 | | | | | $ | 19,401,468 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
员工福利支出
|
| | | | 20,634,246 | | | | | | 41.6 | | | | | | 18,778,964 | | | | | | 36.3 | | | | | | 1,855,282 | | | | | | 9.9 | | |
折旧和摊销费用
|
| | | | 3,500,469 | | | | | | 7.1 | | | | | | 3,085,724 | | | | | | 6.0 | | | | | | 414,745 | | | | | | 13.4 | | |
专业服务费
|
| | | | 5,048,114 | | | | | | 10.2 | | | | | | 15,508,682 | | | | | | 30.0 | | | | | | (10,460,568) | | | | | | (67.4) | | |
办公费
|
| | | | 1,329,449 | | | | | | 2.7 | | | | | | 1,019,819 | | | | | | 2.0 | | | | | | 309,630 | | | | | | 30.4 | | |
贸易应收账款准备
|
| | | | 6,447,110 | | | | | | 13.0 | | | | | | 2,888,417 | | | | | | 5.6 | | | | | | 3,558,693 | | | | | | 123.2 | | |
报废存货备抵
|
| | | | (323,492) | | | | | | (0.7) | | | | | | — | | | | | | — | | | | | | (323,492) | | | | | | (100.0) | | |
税费和附加费
|
| | | | 3,196,939 | | | | | | 6.4 | | | | | | 3,065,689 | | | | | | 5.9 | | | | | | 131,250 | | | | | | 4.3 | | |
银行手续费和汇兑差额
|
| | | | 5,120,896 | | | | | | 10.3 | | | | | | 1,636,971 | | | | | | 3.2 | | | | | | 3,483,925 | | | | | | 212.8 | | |
其他
|
| | | | 4,633,282 | | | | | | 9.3 | | | | | | 5,680,325 | | | | | | 11.0 | | | | | | (1,047,043) | | | | | | (18.4) | | |
合计
|
| | | | 49,587,013 | | | | | | 100.0 | | | | | | 51,664,591 | | | | | | 100.0 | | | | | | (2,077,578) | | | | | | (4.0) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
检测和临床试验费用
|
| | | | 69,020,560 | | | | | | 55.7 | | | | | | 47,673,861 | | | | | | 38.4 | | | | | | 21,346,699 | | | | | | 44.8 | | |
咨询服务费
|
| | | | 8,411,505 | | | | | | 6.8 | | | | | | 41,536,873 | | | | | | 33.5 | | | | | | (33,125,368) | | | | | | (79.7) | | |
员工福利支出
|
| | | | 33,812,314 | | | | | | 27.3 | | | | | | 24,577,264 | | | | | | 19.8 | | | | | | 9,235,050 | | | | | | 37.6 | | |
折旧和摊销费用
|
| | | | 6,323,641 | | | | | | 5.1 | | | | | | 4,934,566 | | | | | | 4.0 | | | | | | 1,389,075 | | | | | | 28.1 | | |
办公楼和租赁费
|
| | | | 588,586 | | | | | | 0.5 | | | | | | 565,381 | | | | | | 0.5 | | | | | | 23,205 | | | | | | 4.1 | | |
其他
|
| | | | 5,704,501 | | | | | | 4.6 | | | | | | 4,763,264 | | | | | | 3.8 | | | | | | 941,237 | | | | | | 19.8 | | |
合计 | | | | | 123,861,107 | | | | | | 100.0 | | | | | | 124,051,209 | | | | | | 100.0 | | | | | | (190,102) | | | | | | (0.2) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
鼠兔重组新冠肺炎疫苗
|
| | | | 82,214,199 | | | | | | 66.4 | | | | | | 80,241,252 | | | | | | 64.7 | | | | | | 1,972,947 | | | | | | 2.5 | | |
鼠兔狂犬病疫苗
|
| | | | 17,519,659 | | | | | | 14.1 | | | | | | 8,965,209 | | | | | | 7.2 | | | | | | 8,554,450 | | | | | | 95.4 | | |
鼠兔YS-0N-001
|
| | | | 4,854,187 | | | | | | 3.9 | | | | | | 10,982,320 | | | | | | 8.9 | | | | | | (6,128,133) | | | | | | (55.8) | | |
鼠兔乙肝疫苗
|
| | | | 5,940,696 | | | | | | 4.8 | | | | | | 9,007,328 | | | | | | 7.3 | | | | | | (3,066,632) | | | | | | (34.0) | | |
鼠兔佐剂
|
| | | | 4,054,248 | | | | | | 3.3 | | | | | | 4,344,773 | | | | | | 3.5 | | | | | | (290,525) | | | | | | (6.7) | | |
YSJATM狂犬病疫苗
|
| | | | 4,275,750 | | | | | | 3.5 | | | | | | 5,221,734 | | | | | | 4.2 | | | | | | (945,984) | | | | | | (18.1) | | |
其他
|
| | | | 5,002,368 | | | | | | 4.0 | | | | | | 5,288,593 | | | | | | 4.2 | | | | | | (286,225) | | | | | | (5.4) | | |
合计 | | | | | 123,861,107 | | | | | | 100.0 | | | | | | 124,051,209 | | | | | | 100.0 | | | | | | (190,102) | | | | | | (0.2) | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
推广和营销服务费
|
| | | | 162,461,330 | | | | | | 87.3 | | | | | | 64,770,329 | | | | | | 88.1 | | | | | | 97,691,001 | | | | | | 150.8 | | |
员工福利支出
|
| | | | 20,283,326 | | | | | | 10.9 | | | | | | 4,049,357 | | | | | | 5.5 | | | | | | 16,233,969 | | | | | | 400.9 | | |
其他
|
| | | | 3,255,048 | | | | | | 1.8 | | | | | | 4,665,573 | | | | | | 6.4 | | | | | | (1,410,525) | | | | | | (30.2) | | |
合计
|
| | |
|
185,999,704
|
| | | |
|
100.0
|
| | | |
|
73,485,259
|
| | | |
|
100.0
|
| | | |
|
112,514,445
|
| | | |
|
153.1
|
| |
截至2009年3月31日的财政年度
|
| |
0 - 90天
|
| |
90 - 180天
|
| |
180 - 365天
|
| |
>365天
|
| |
合计
|
| |||||||||||||||
2022(人民币)
|
| | | | 73,593,680 | | | | | | 64,397,895 | | | | | | 58,064,055 | | | | | | 7,184,920 | | | | | | 203,240,550 | | |
2022(美元)
|
| | | $ | 11,592,842 | | | | | $ | 10,144,276 | | | | | $ | 9,146,538 | | | | | $ | 1,131,804 | | | | | $ | 32,015,460 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
员工福利支出
|
| | | | 41,599,522 | | | | | | 38.7 | | | | | | 89,872,239 | | | | | | 57.9 | | | | | | (48,272,717) | | | | | | (53.7) | | |
折旧和摊销费用
|
| | | | 5,998,308 | | | | | | 5.6 | | | | | | 9,489,983 | | | | | | 6.1 | | | | | | (3,491,675) | | | | | | (36.8) | | |
专业服务费
|
| | | | 30,680,853 | | | | | | 28.5 | | | | | | 33,649,233 | | | | | | 21.7 | | | | | | (2,968,380) | | | | | | (8.8) | | |
办公费
|
| | | | 2,766,021 | | | | | | 2.6 | | | | | | 4,020,338 | | | | | | 2.6 | | | | | | (1,254,317) | | | | | | (31.2) | | |
贸易应收账款准备
|
| | | | 5,082,725 | | | | | | 4.7 | | | | | | 6,998,818 | | | | | | 4.5 | | | | | | (1,916,093) | | | | | | (27.4) | | |
报废存货备抵
|
| | | | 4,393,629 | | | | | | 4.1 | | | | | | — | | | | | | — | | | | | | 4,393,629 | | | | | | 100.0 | | |
税费和附加费
|
| | | | 5,379,934 | | | | | | 5.0 | | | | | | 4,004,265 | | | | | | 2.6 | | | | | | 1,375,669 | | | | | | 34.4 | | |
其他
|
| | | | 11,719,508 | | | | | | 10.8 | | | | | | 7,299,510 | | | | | | 4.6 | | | | | | 4,419,998 | | | | | | 60.4 | | |
合计 | | | | | 107,620,500 | | | | | | 100.0 | | | | | | 155,334,386 | | | | | | 100 | | | | | | (47,713,886) | | | | | | (30.7) | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
检测和临床试验费用
|
| | | | 74,166,285 | | | | | | 35.1 | | | | | | 20,480,320 | | | | | | 21.7 | | | | | | 53,685,965 | | | | | | 262.1 | | |
咨询服务费
|
| | | | 59,975,917 | | | | | | 28.4 | | | | | | 31,492,876 | | | | | | 33.4 | | | | | | 28,483,041 | | | | | | 90.4 | | |
员工福利支出
|
| | | | 56,513,100 | | | | | | 26.8 | | | | | | 29,178,337 | | | | | | 30.9 | | | | | | 27,334,763 | | | | | | 93.7 | | |
折旧及摊销
|
| | | | 10,796,480 | | | | | | 5.1 | | | | | | 6,331,638 | | | | | | 6.7 | | | | | | 4,464,842 | | | | | | 70.5 | | |
办公楼和租赁费
|
| | | | 1,039,327 | | | | | | 0.5 | | | | | | 3,446,146 | | | | | | 3.7 | | | | | | (2,406,819) | | | | | | (69.8) | | |
其他
|
| | | | 8,731,154 | | | | | | 4.1 | | | | | | 3,457,827 | | | | | | 3.6 | | | | | | 5,273,327 | | | | | | 152.5 | | |
合计 | | | | | 211,222,263 | | | | | | 100.0 | | | | | | 94,387,144 | | | | | | 100.0 | | | | | | 116,835,119 | | | | | | 123.8 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
鼠兔重组新冠肺炎疫苗
|
| | | | 127,773,439 | | | | | | 60.5 | | | | | | 33,903,400 | | | | | | 35.9 | | | | | | 93,870,039 | | | | | | 276.9 | | |
鼠兔狂犬病疫苗
|
| | | | 24,272,368 | | | | | | 11.5 | | | | | | 13,718,774 | | | | | | 14.5 | | | | | | 10,553,594 | | | | | | 76.9 | | |
鼠兔YS-0N-001
|
| | | | 16,528,066 | | | | | | 7.8 | | | | | | 4,312,590 | | | | | | 4.6 | | | | | | 12,215,476 | | | | | | 283.3 | | |
鼠兔乙肝疫苗
|
| | | | 16,438,478 | | | | | | 7.8 | | | | | | 7,536,556 | | | | | | 8.0 | | | | | | 8,901,922 | | | | | | 118.1 | | |
鼠兔佐剂
|
| | | | 8,171,893 | | | | | | 3.9 | | | | | | 26,036,582 | | | | | | 27.6 | | | | | | (17,864,689) | | | | | | (68.6) | | |
YSJA-TM狂犬病疫苗
|
| | | | 7,579,877 | | | | | | 3.6 | | | | | | 3,939,781 | | | | | | 4.2 | | | | | | 3,640,096 | | | | | | 92.4 | | |
其他
|
| | | | 10,458,142 | | | | | | 4.9 | | | | | | 4,939,461 | | | | | | 5.2 | | | | | | 5,518,681 | | | | | | 111.7 | | |
合计 | | | | | 211,222,263 | | | | | | 100.0 | | | | | | 94,387,144 | | | | | | 100.0 | | | | | | 116,835,119 | | | | | | 123.8 | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2021
|
| ||||||||||||||||||||||||
| | |
人民币
|
| |
$
|
| |
人民币
|
| |
人民币
|
| |
$
|
| |
人民币
|
| ||||||||||||||||||
运营中使用的净现金
活动 |
| | | | (107,395,153) | | | | | | (15,126,504) | | | | | | (176,984,374) | | | | | | (173,545,357) | | | | | | (27,337,727) | | | | | | (246,610,437) | | |
用于投资的现金净额
活动 |
| | | | (19,024,351) | | | | | | (2,679,561) | | | | | | (203,390,377) | | | | | | (298,923,958) | | | | | | (47,087,987) | | | | | | (104,238,941) | | |
融资活动提供的现金净额
|
| | | | 51,907,325 | | | | | | 7,311,097 | | | | | | 43,885,865 | | | | | | 364,558,145 | | | | | | 57,427,010 | | | | | | 739,258,696 | | |
外汇汇率对现金及现金等价物的影响
|
| | | | 30,471,942 | | | | | | 4,291,943 | | | | | | (4,446,301) | | | | | | (11,478,411) | | | | | | (1,808,136) | | | | | | (2,674) | | |
现金和现金等价物净减少
|
| | | | (44,040,237) | | | | | | (6,203,025) | | | | | | (340,935,187) | | | | | | (119,389,581) | | | | | | (18,806,840) | | | | | | 388,406,644 | | |
会计年度开始时的现金和受限现金
|
| | | | 271,067,503 | | | | | | 38,179,597 | | | | | | 390,457,084 | | | | | | 390,457,084 | | | | | | 61,506,740 | | | | | | 2,050,440 | | |
财政年度末的现金和限制性现金
|
| | | | 227,027,266 | | | | | | 31,976,572 | | | | | | 49,521,897 | | | | | | 271,067,503 | | | | | | 42,699,900 | | | | | | 390,457,084 | | |
还款日
|
| |
分期付款
|
| |||
2025年4月7日
|
| | | $ | 6,400,000 | | |
2025年7月7日
|
| | | | 6,400,000 | | |
2025年10月7日
|
| | | | 6,400,000 | | |
2026年1月7日
|
| | | | 6,400,000 | | |
2026年4月7日
|
| | | | 6,400,000 | | |
2026年7月7日
|
| | | | 8,000,000 | | |
合计 | | | | $ | 40,000,000 | | |
净销售额层级
|
| |
版税
|
| |||
在一个财政年度内版税产品年净销售额低于或等于5亿元人民币的部分
|
| | | | 1.5% | | |
一个财政年度版税产品年净销售额大于5亿元人民币但小于等于10亿元人民币的部分
|
| | | | 3.0% | | |
一个财政年度版税产品年净销售额超过10亿元的部分
|
| | | | 3.5% | | |
净销售额层级
|
| |
版税
|
| |||
在一个财政年度内版税产品年净销售额低于或等于5亿元人民币的部分
|
| | | | 0.6% | | |
一个财政年度版税产品年净销售额大于5亿元人民币但小于等于10亿元人民币的部分
|
| | | | 1.2% | | |
一个财政年度版税产品年净销售额超过10亿元的部分
|
| | | | 1.4% | | |
截至2009年3月31日的财政年度
|
| |
截至2022年3月31日
|
| |
截至2022年9月30日
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||
2023
|
| | | | 4,947,481 | | | | | $ | 779,352 | | | | | | 5,748,070 | | | | | $ | 809,610 | | |
2024
|
| | | | 4,837,260 | | | | | | 761,989 | | | | | | 5,029,426 | | | | | | 708,390 | | |
2025
|
| | | | 4,922,251 | | | | | | 775,377 | | | | | | 3,921,138 | | | | | | 552,289 | | |
2026
|
| | | | 1,479,661 | | | | | | 233,084 | | | | | | 158,029 | | | | | | 22,257 | | |
2027年及以后
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
租赁支付总额
|
| | | | 16,186,653 | | | | | | 2,549,802 | | | | |
|
14,856,663
|
| | | |
|
2,092,546
|
| |
少:利息
|
| | | | (1,259,141) | | | | | | (198,346) | | | | | | (928,262) | | | | | | (130,744) | | |
经营租赁负债现值
|
| | | | 14,927,512 | | | | | $ | 2,351,456 | | | | |
|
13,928,401
|
| | | | $ | 1,961,802 | | |
名称
|
| |
年龄
|
| |
职位/头衔
|
|
张 | | |
66
|
| | 董事和董事长 | |
邵辉博士 | | |
54
|
| |
董事、总裁和首席执行官
|
|
陈伯丹先生 | | |
49
|
| | 董事 | |
阿吉特·谢蒂博士 | | |
76
|
| | 独立董事 | |
维伦·梅塔博士 | | |
72
|
| | 独立董事 | |
斯坦利·常毅博士 | | |
64
|
| | 独立董事 | |
童少京先生 | | |
51
|
| | 独立董事 | |
Zenaida Reynoso Mojares博士 | | |
64
|
| | 首席医疗官 | |
吴春元女士 | | |
45
|
| | 首席财务官 | |
刘元元博士 | | |
36
|
| | 疫苗研究负责人 | |
Gang Li先生 | | |
41
|
| | 市场销售主管 | |
承保人姓名
|
| |
普通股
选项获奖 |
| |
练习
每件价格 普通股 分享($) |
| |
授予日期
|
| |
过期日期
|
| ||||||
张毅先生
|
| | | | 1,037,549 | | | | | | 2.1956 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
刘元元博士
|
| | | | 23,811 | | | | | | 4.0724 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
Gang Li先生
|
| | | | 10,965 | | | | | | 4.0724 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
其他450多名员工
|
| | | | 2,399,221 | | | | | | 4.0724 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
| | |
编号
|
| |
%
|
| ||||||
董事和执行官(1): | | | | | | | | | | | | | |
张毅先生(2)
|
| | | | 48,615,000 | | | | | | 52.24% | | |
邵辉博士(3)
|
| | | | 2,002,780 | | | | | | 2.15% | | |
博坦先生(4)
|
| | | | 3,853,475 | | | | | | 4.14% | | |
阿吉特·谢蒂博士
|
| | | | * | | | | | | * | | |
维伦·梅塔博士
|
| | | | * | | | | | | * | | |
斯坦利·常毅博士
|
| | | | * | | | | | | * | | |
童少京先生
|
| | | | — | | | | | | | | |
泽纳伊达·雷诺索·莫哈雷斯博士
|
| | | | — | | | | | | | | |
吴春元女士
|
| | | | * | | | | | | * | | |
袁柳博士
|
| | | | — | | | | | | | | |
Gang Li先生
|
| | | | — | | | | | | | | |
作为一个组的所有董事和高管
|
| | | | 54,858,366 | | | | | | 58.95% | | |
主要股东: | | | | | | | | | | | | | |
张毅先生及其附属单位(2)
|
| | | | 48,615,000 | | | | | | 52.24% | | |
| | |
受益证券
在此产品之前拥有 |
| |
待售证券
此产品中的 |
| |
受益证券
本次发行后拥有的 |
| |||||||||||||||||||||
销售证券持有人名称
|
| |
普通
个共享 |
| |
%(1)
|
| |
普通
个共享 |
| |
普通
股份(1)(2) |
| |
%(1)(2)
|
| |||||||||||||||
辉少(3)
|
| | | | 2,002,780 | | | | | | 2.2% | | | | | | 2,002,780 | | | | | | — | | | | | | — | | |
吴春源(4)
|
| | | | 97,500 | | | | | | * | | | | | | 97,500 | | | | | | — | | | | | | — | | |
Sunangal Ajit Shetty&Christine Maria M.Clerinx(5)
|
| | | | 27,500 | | | | | | * | | | | | | 27,500 | | | | | | — | | | | | | — | | |
Viren T MEHTA & Amita RODMAN(作为V Mehta RLT & A Rodman RLT的受托人)(6)
|
| | | | 35,000 | | | | | | * | | | | | | 35,000 | | | | | | — | | | | | | — | | |
Stanley Yi Chang(7)
|
| | | | 82,111 | | | | | | * | | | | | | 82,111 | | | | | | — | | | | | | — | | |
Viren T Mehta(8)
|
| | | | 72,500 | | | | | | * | | | | | | 72,500 | | | | | | — | | | | | | — | | |
Sunangal Ajit Shetty(9)
|
| | | | 72,500 | | | | | | * | | | | | | 72,500 | | | | | | — | | | | | | — | | |
Asia Ventures II L.P.(十)
|
| | | | 2,718,499 | | | | | | 2.9% | | | | | | 2,718,499 | | | | | | — | | | | | | — | | |
F—Prime Capital Partners医疗基金III LP(11)
|
| | | | 1,165,071 | | | | | | 1.3% | | | | | | 1,165,071 | | | | | | — | | | | | | — | | |
HH SUM XXXVI控股有限公司(12)
|
| | | | 751,790 | | | | | | * | | | | | | 751,790 | | | | | | — | | | | | | — | | |
附属于OrbiMed的实体(13)
|
| | | | 4,298,465 | | | | | | 4.6% | | | | | | 4,298,465 | | | | | | — | | | | | | — | | |
海通旭宇国际有限公司(14)
|
| | | | 187,948 | | | | | | * | | | | | | 187,948 | | | | | | — | | | | | | — | | |
| | |
受益证券
在此产品之前拥有 |
| |
待售证券
此产品中的 |
| |
受益证券
在此之后拥有 提供服务 |
| |||||||||||||||||||||
销售证券持有人名称
|
| |
普通
个共享 |
| |
%(1)
|
| |
普通
个共享 |
| |
普通
股份(1)(2) |
| |
%(1)(2)
|
| |||||||||||||||
Epiphron Capital(Hong Kong)Limited(15)
|
| | | | 701,148 | | | | | | * | | | | | | 701,148 | | | | | | — | | | | | | — | | |
3W环球投资有限公司(16)
|
| | | | 187,948 | | | | | | * | | | | | | 187,948 | | | | | | — | | | | | | — | | |
大洋洲投资基金II LP(17)
|
| | | | 4,105,596 | | | | | | 4.4% | | | | | | 4,105,596 | | | | | | — | | | | | | — | | |
AIHC大师基金(18)
|
| | | | 718,480 | | | | | | * | | | | | | 718,480 | | | | | | — | | | | | | — | | |
3W全球基金(19)
|
| | | | 2,052,798 | | | | | | 2.2% | | | | | | 2,052,798 | | | | | | — | | | | | | — | | |
美盛中国成长基金II L.P.(20)
|
| | | | 1,129,039 | | | | | | 1.2% | | | | | | 1,129,039 | | | | | | — | | | | | | — | | |
超弦资本大师基金LP(21)
|
| | | | 307,920 | | | | | | * | | | | | | 307,920 | | | | | | — | | | | | | — | | |
五道口资本有限公司(22)
|
| | | | 307,920 | | | | | | * | | | | | | 307,920 | | | | | | — | | | | | | — | | |
GENEX中国成长基金(23只)
|
| | | | 205,280 | | | | | | * | | | | | | 205,280 | | | | | | — | | | | | | — | | |
佐剂全球卫生技术基金,L.P.(24)
|
| | | | 2,436,298 | | | | | | 2.6% | | | | | | 2,436,298 | | | | | | — | | | | | | — | | |
辅助性全球卫生技术基金DE,L.P.(24)
|
| | | | 466,671 | | | | | | * | | | | | | 466,671 | | | | | | — | | | | | | — | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股(香港)有限公司 | | | | | | | | | | | | | | | | | | | |
YS集团代收应收账款
|
| | | | 30,088,833 | | | | | | 2,966,777 | | | | | $ | 459,412 | | |
还款给YS集团
|
| | | | | | | | | | 33,055,610 | | | | | $ | 5,118,732 | | |
|
美国证券交易委员会注册费
|
| | | $ | 4,108.48 | | |
|
FINRA备案费
|
| | | | * | | |
|
律师费和开支
|
| | | | * | | |
|
会计师手续费和费用
|
| | | $ | 15,000 | | |
|
打印费
|
| | | $ | 58,000 | | |
|
转会代理费和费用
|
| | | | * | | |
|
杂项成本
|
| | | $ | 600 | | |
|
合计
|
| | | $ | 77,708.48 | | |
内容
|
| |
页
|
| |||
独立注册会计师事务所报告(PCAOB ID 2388)
|
| | | | F-2 | | |
截至2022年和2021年3月31日的综合资产负债表
|
| | | | F-3 | | |
截至2022年和2021年3月31日止年度的综合经营报表和全面亏损报表
|
| | | | F-5 | | |
截至2022年3月31日的年度股东赤字变动综合报表
和2021年 |
| | | | F-6 | | |
截至2022年和2021年3月31日止年度合并现金流量表
|
| | | | F-7 | | |
合并财务报表附注
|
| | | | F-8 | | |
截至2022年9月30日(未经审计)和2022年3月31日的简明综合资产负债表
|
| | | | F-41 | | |
截至2022年和2021年9月30日的六个月未经审计的简明综合经营报表和全面亏损
|
| | | | F-42 | | |
截至2022年9月30日和2021年9月30日的六个月未经审计的股东赤字变化简明综合报表
|
| | | | F-43 | | |
截至2022年和2021年9月30日止六个月未经审计的现金流量简明综合报表
|
| | | | F-44 | | |
未经审计的简明合并财务报表附注
|
| | | | F-45 | | |
|
![]() |
|
![]() |
|
独立注册会计师事务所报告
|
| ||
|
致
董事会和股东 益生生物股份有限公司 |
| |||
|
对财务报表的意见
我们审计了亿盛生物股份有限公司及其附属公司(“本公司”)截至2022年3月31日、2021年3月31日和2021年3月31日的合并资产负债表,以及截至2022年3月31日的两年期间各年度的相关综合经营报表和全面亏损、股东赤字变动、现金流量以及相关附注(统称财务报表)。我们认为,财务报表在所有重要方面都公平地反映了本公司截至2022年3月31日、2022年3月31日和2021年3月31日的财务状况,以及截至2022年3月31日的两年期间各年度的经营结果和现金流量,符合美国公认的会计原则。
|
| |||
|
方便翻译
我们的审计还包括将人民币金额转换为美元金额,我们认为,此类转换符合财务报表附注3所述的基础。这样的美元数额,完全是为了方便人民Republic of China以外的读者。
|
| |||
| 意见基础 | | |||
|
这些财务报表由公司管理层负责。我们的责任是根据我们的审计对公司的财务报表发表意见。我们是一家在美国上市公司会计监督委员会(PCAOB)注册的公共会计师事务所,根据美国联邦证券法以及美国证券交易委员会和PCAOB的适用规则和法规,我们必须与公司保持独立。
|
| |||
|
我们按照PCAOB的标准进行审核。这些标准要求我们计划和执行审计,以获得关于财务报表是否没有重大错报的合理保证,无论是由于错误还是舞弊。本公司并无被要求对其财务报告的内部控制进行审计,我们也没有受聘进行审计。作为我们审计的一部分,我们被要求了解财务报告的内部控制,但不是为了对公司财务报告内部控制的有效性发表意见。因此,我们不表达这样的意见。
|
| |||
|
我们的审计包括执行评估财务报表重大错报风险的程序,无论是由于错误还是欺诈,以及执行应对这些风险的程序。这些程序包括在测试的基础上审查与财务报表中的数额和披露有关的证据。我们的审计还包括评价管理层使用的会计原则和作出的重大估计,以及评价财务报表的整体列报。我们相信,我们的审计为我们的观点提供了合理的基础。
/S/魏伟,有限责任公司
纽约法拉盛 2022年9月28日
自2022年以来,我们一直担任本公司的审计师。
|
|
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | $ | 42,699,900 | | |
应收账款净额
|
| | | | 214,502,737 | | | | | | 308,555,105 | | | | | | 48,605,133 | | |
预付款给供应商
|
| | | | 11,458,564 | | | | | | 10,648,306 | | | | | | 1,677,374 | | |
关联方应付金额
|
| | | | 30,088,833 | | | | | | — | | | | | | — | | |
库存,净额
|
| | | | 81,439,883 | | | | | | 166,505,565 | | | | | | 26,228,784 | | |
预付费用和其他流动资产
|
| | | | 5,257,185 | | | | | | 7,987,914 | | | | | | 1,258,295 | | |
流动资产总额
|
| | | | 733,204,286 | | | | | | 764,764,393 | | | | | | 120,469,486 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备,净额
|
| | | | 236,204,959 | | | | | | 550,153,110 | | | | | | 86,662,851 | | |
经营性租赁使用权资产,净额
|
| | | | 17,245,924 | | | | | | 14,850,283 | | | | | | 2,339,290 | | |
递延税金资产净额
|
| | | | 7,976,206 | | | | | | 3,039,084 | | | | | | 478,732 | | |
无形资产净值
|
| | | | 83,778,603 | | | | | | 80,717,978 | | | | | | 12,715,097 | | |
其他非流动资产
|
| | | | 88,765,094 | | | | | | 28,228,293 | | | | | | 4,446,661 | | |
非流动资产合计
|
| | | | 433,970,786 | | | | | | 676,988,748 | | | | | | 106,642,631 | | |
总资产
|
| | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | $ | 227,112,117 | | |
负债、夹层股权和股东亏损
|
| | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - Current
|
| | | | — | | | | | | 111,733,754 | | | | | $ | 17,600,856 | | |
应付账款
|
| | | | 16,383,236 | | | | | | 30,811,100 | | | | | | 4,853,518 | | |
应计费用和其他负债
|
| | | | 322,750,471 | | | | | | 326,751,353 | | | | | | 51,471,496 | | |
经营租赁负债 - 流动
|
| | | | 3,785,642 | | | | | | 4,322,252 | | | | | | 680,863 | | |
延期政府拨款 - Current
|
| | | | 2,121,645 | | | | | | 2,295,701 | | | | | | 361,630 | | |
流动负债总额
|
| | | | 345,040,994 | | | | | | 475,914,160 | | | | | | 74,968,363 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - 非流动
|
| | | | 1,103,609 | | | | | | 253,928,000 | | | | | | 40,000,000 | | |
经营性租赁负债 - 非流动
|
| | | | 13,550,359 | | | | | | 10,605,260 | | | | | | 1,670,593 | | |
延期政府拨款 - 非当前
|
| | | | 30,884,246 | | | | | | 30,053,517 | | | | | | 4,734,179 | | |
非流动负债合计
|
| | | | 45,538,214 | | | | | | 294,586,777 | | | | | | 46,404,772 | | |
总负债
|
| | | | 390,579,208 | | | | | | 770,500,937 | | | | | | 121,373,135 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;已发行和已发行21,548,589股)
|
| | | | 410,327,208 | | | | | | 458,074,468 | | | | | | 72,158,166 | | |
B系列可赎回可转换优先股
(每股面值0.000005美元,1亿股 授权;已发行65,414,858股, 未完成) |
| | | | 875,131,363 | | | | | | 912,146,924 | | | | | | 143,685,915 | | |
夹层总股本
|
| | | | 1,285,458,571 | | | | | | 1,370,221,392 | | | | | | 215,844,081 | | |
承付款和或有事项
|
| | | | — | | | | | | — | | | | | | — | | |
股东亏损 | | | | | | | | | | | | | | | | | | | |
普通股,每股面值0.000005美元,授权股份99.5亿股,已发行和已发行股份247,311,533股*
|
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,257 | | |
新增实收资本
|
| | | | 800,806,378 | | | | | | 808,502,018 | | | | | | 127,359,254 | | |
累计亏损
|
| | | | (1,353,900,436) | | | | | | (1,590,567,163) | | | | | | (250,554,041) | | |
累计其他综合收益
|
| | | | 44,223,373 | | | | | | 83,087,979 | | | | | | 13,088,431 | | |
股东亏损总额
|
| | | | (508,862,707) | | | | | | (698,969,188) | | | | | | (110,105,099) | | |
总负债、夹层权益和股东亏损
|
| | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | $ | 227,112,117 | | |
|
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
收入 | | | | | 257,015,929 | | | | | | 502,949,894 | | | | | $ | 79,227,166 | | |
收入成本
|
| | | | 59,656,877 | | | | | | 117,066,090 | | | | | | 18,440,832 | | |
毛利
|
| | | | 197,359,052 | | | | | | 385,883,804 | | | | | | 60,786,334 | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | 73,485,259 | | | | | | 185,999,704 | | | | | | 29,299,597 | | |
一般和行政
|
| | | | 155,334,386 | | | | | | 107,620,500 | | | | | | 16,952,916 | | |
研发
|
| | | | 94,387,144 | | | | | | 211,222,263 | | | | | | 33,272,780 | | |
总运营费用
|
| | | | 323,206,789 | | | | | | 504,842,467 | | | | | | 79,525,293 | | |
运营亏损
|
| | | | (125,847,737) | | | | | | (118,958,663) | | | | | | (18,738,959) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | |
所得税相关滞纳金
|
| | | | (11,464,741) | | | | | | — | | | | | | — | | |
与所得税以外的税种相关的滞纳金
|
| | | | (7,261,947) | | | | | | (231,231) | | | | | | (36,425) | | |
与社保相关的滞纳金
|
| | | | (7,701,793) | | | | | | (1,852,378) | | | | | | (291,796) | | |
政府拨款
|
| | | | 3,530,405 | | | | | | 23,020,413 | | | | | | 3,626,290 | | |
财务费用,净额
|
| | | | (29,689,927) | | | | | | (2,717,433) | | | | | | (428,064) | | |
其他收入(支出),净额
|
| | | | 4,063,743 | | | | | | (327,987) | | | | | | (51,666) | | |
其他(费用)收入合计,净额
|
| | | | (48,524,260) | | | | | | 17,891,384 | | | | | | 2,818,339 | | |
所得税前亏损
|
| | | | (174,371,997) | | | | | | (101,067,279) | | | | | | (15,920,620) | | |
所得税费用
|
| | | | (17,454,245) | | | | | | (4,937,122) | | | | | | (777,720) | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (16,610,297) | | | | | | (130,662,326) | | | | | | (20,582,579) | | |
易升生物股份有限公司净亏损
|
| | | | (208,436,539) | | | | | | (236,666,727) | | | | | $ | (37,280,919) | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | $ | (16,698,340) | | |
其他综合收益:外币折算
收获 |
| | | | 22,455,217 | | | | | | 38,864,606 | | | | | | 6,122,146 | | |
全面亏损
|
| | | | (169,371,025) | | | | | | (67,139,795) | | | | | $ | (10,576,194) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.78) | | | | | | (0.43) | | | | | $ | (0.07) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
| | |
普通股*
|
| |
额外的
实收 大写 |
| |
赤字
|
| |
累计
其他 全面 收入 |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |||||||||||||||
截至2020年3月31日的余额
|
| | | | 212,883,618 | | | | | | 6,797 | | | | | | 276,368,115 | | | | | | (1,145,463,897) | | | | | | 21,768,156 | | | | | | (847,320,829) | | |
股东的贡献
|
| | | | 34,427,915 | | | | | | 1,181 | | | | | | 447,681,763 | | | | | | — | | | | | | — | | | | |
|
447,682,944
|
| |
增加到赎回价值
可兑换可赎回优先选项 个共享 |
| | | | — | | | | | | — | | | | | | — | | | | | | (16,610,297) | | | | | | — | | | | |
|
(16,610,297)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (191,826,242) | | | | | | | | | | |
|
(191,826,242)
|
| |
基于股份的薪酬
|
| | | | — | | | | | | — | | | | | | 76,756,500 | | | | | | — | | | | | | — | | | | |
|
76,756,500
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 22,455,217 | | | | |
|
22,455,217
|
| |
截至2021年3月31日的余额
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 800,806,378 | | | | | | (1,353,900,436) | | | | | | 44,223,373 | | | | | | (508,862,707) | | |
增加到赎回价值
可兑换可赎回优先选项 个共享 |
| | | | — | | | | | | — | | | | | | — | | | | | | (130,662,326) | | | | | | — | | | | |
|
(130,662,326)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (106,004,401) | | | | | | — | | | | |
|
(106,004,401)
|
| |
基于股份的薪酬
|
| | | | — | | | | | | — | | | | | | 7,764,448 | | | | | | — | | | | | | — | | | | |
|
7,764,448
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | (68,808) | | | | | | — | | | | | | 38,864,606 | | | | |
|
38,795,798
|
| |
截至2022年3月31日的余额(单位:人民币)
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 808,502,018 | | | | | | (1,590,567,163) | | | | | | 83,087,979 | | | | | | (698,969,188) | | |
截至2022年3月31日的余额(单位:美元)
|
| | | | 247,311,533 | | | | | $ | 1,257 | | | | | $ | 127,359,254 | | | | | $ | (250,554,041) | | | | | $ | 13,088,431 | | | | | $ | (110,105,099) | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
经营活动现金流: | | | | | | | | | | | | | | | | | | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | $ | (16,698,340) | | |
将净亏损与经营活动中使用的现金净额进行调整: | | | | | | | | | | | | | | | | | | | |
递延所得税
|
| | | | 17,454,245 | | | | | | 4,937,120 | | | | | | 777,720 | | |
财产、厂房和设备折旧
|
| | | | 22,240,060 | | | | | | 24,475,736 | | | | | | 3,855,540 | | |
无形资产摊销
|
| | | | 5,665,735 | | | | | | 6,678,233 | | | | | | 1,051,988 | | |
处置财产、厂房和设备的损失
|
| | | | 24,876 | | | | | | 273,982 | | | | | | 43,159 | | |
基于股份的薪酬
|
| | | | 76,756,500 | | | | | | 7,764,448 | | | | | | 1,223,094 | | |
应收账款减值
|
| | | | 6,414,634 | | | | | | 5,084,925 | | | | | | 801,003 | | |
将存货减记为可变现净值
|
| | | | 1,109,400 | | | | | | 4,393,630 | | | | | | 692,106 | | |
非现金租赁费用
|
| | | | 2,233,089 | | | | | | 3,787,628 | | | | | | 596,646 | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
库存
|
| | | | (68,728,378) | | | | | | (89,459,313) | | | | | | (14,092,075) | | |
应收账款
|
| | | | (220,734,141) | | | | | | (99,137,291) | | | | | | (15,616,599) | | |
关联方应付金额
|
| | | | (3,086,330) | | | | | | 30,088,833 | | | | | | 4,739,742 | | |
预付费用和其他流动资产
|
| | | | 146,767,686 | | | | | | 59,229,801 | | | | | | 9,330,172 | | |
应付账款
|
| | | | (4,424,337) | | | | | | 14,427,864 | | | | | | 2,272,749 | | |
应付关联方金额
|
| | | | (245,808) | | | | | | — | | | | | | — | | |
应计费用和其他负债
|
| | | | 140,210 | | | | | | (35,633,487) | | | | | | (5,613,164) | | |
延期政府拨款
|
| | | | (44,290) | | | | | | (656,673) | | | | | | (103,442) | | |
应付所得税
|
| | | | (34,105,055) | | | | | | — | | | | | | — | | |
经营性租赁负债
|
| | | | (2,222,291) | | | | | | (3,796,392) | | | | | | (598,027) | | |
经营活动中使用的净现金
|
| | | | (246,610,437) | | | | | | (173,545,357) | | | | | | (27,337,727) | | |
投资活动现金流: | | | | | | | | | | | | | | | | | | | |
处置财产、厂房和设备所得收益
|
| | | | 644,842 | | | | | | 8,000 | | | | | | 1,260 | | |
购置房产、厂房和设备
|
| | | | (104,883,783) | | | | | | (295,314,351) | | | | | | (46,519,384) | | |
购买无形资产
|
| | | | — | | | | | | (3,617,607) | | | | | | (569,863) | | |
投资活动中使用的净现金
|
| | | | (104,238,941) | | | | | | (298,923,958) | | | | | | (47,087,987) | | |
融资活动的现金流: | | | | | | | | | | | | | | | | | | | |
发行夹层股权所得收益
|
| | | | 729,412,999 | | | | | | — | | | | | | — | | |
股东的贡献
|
| | | | 1,589,236 | | | | | | — | | | | | | — | | |
银行贷款和其他借款的收益
|
| | | | 32,253,609 | | | | | | 414,116,587 | | | | | | 65,233,702 | | |
偿还银行贷款和其他借款
|
| | | | (160,407,571) | | | | | | (49,558,442) | | | | | | (7,806,692) | | |
关联方借款收益
|
| | | | 299,757,219 | | | | | | — | | | | | | — | | |
偿还关联方借款
|
| | | | (163,346,796) | | | | | | — | | | | | | — | | |
融资活动提供的现金净额
|
| | | | 739,258,696 | | | | | | 364,558,145 | | | | | | 57,427,010 | | |
汇率对现金的影响
|
| | | | (2,674) | | | | | | (11,478,411) | | | | | | (1,808,136) | | |
现金净增(减)
|
| | | | 388,406,644 | | | | | | (119,389,581) | | | | | | (18,806,840) | | |
年初现金
|
| | | | 2,050,440 | | | | | | 390,457,084 | | | | | | 61,506,740 | | |
年终现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | $ | 42,699,900 | | |
现金流量信息补充披露: | | | | | | | | | | | | | | | | | | | |
缴纳所得税
|
| | | | 34,105,055 | | | | | | — | | | | | $ | — | | |
已支付利息
|
| | | | 8,124,572 | | | | | | 2,404,357 | | | | | $ | 378,746 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 16,610,297 | | | | | | 130,662,326 | | | | | $ | 20,582,579 | | |
为相关经营租赁负债确认的经营权资产
|
| | | | 15,048,446 | | | | | | 1,516,478 | | | | | $ | 238,883 | | |
免除对关联方的欠款
|
| | | | 446,092,527 | | | | | | — | | | | | $ | — | | |
|
法人
|
| |
业务性质
|
| |
注册日期
|
| |
公司注册地
|
|
|
益生生物股份有限公司
(“YS Biophma”) |
| | 控股公司 | | |
2020年11月16日
|
| | 开曼群岛 | |
|
亿盛生物(香港)控股有限公司
(“香港益生生物”) |
| | 控股公司 | | |
2020年12月28日
|
| | 香港 | |
| [br]益生生物(新加坡)有限公司有限公司
(“新加坡益生”)* |
| | 疫苗和治疗性生物制品的研究和开发 | | |
2009年11月28日
|
| | 新加坡 | |
|
益生美国生物制药有限公司
(“美国益生”) |
| | 疫苗和治疗性生物制品的研究 | | |
2009年9月29日
|
| | 美国 | |
|
辽宁益生生物制药有限公司
(“辽宁益生”)** |
| | 疫苗和治疗性生物制品的研发、制造和商业化 | | | 1994年5月26日 | | | 中华人民共和国 | |
|
北京益生生物科技有限公司
(“北京益生”) |
| | 疫苗和治疗性生物制品的研究和开发 | | | 2021年2月4日 | | | 中华人民共和国 | |
| | |
截至3月31日
|
| |
截至的年度
3月31日 |
| ||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2021
|
| ||||||||||||
外币
|
| |
资产负债表
|
| |
资产负债表
|
| |
损益
|
| |
损益
|
| ||||||||||||
人民币:1us$
|
| | | | 6.3482 | | | | | | 6.5713 | | | | | | 6.4598 | | | | | | 6.8282 | | |
人民币:1美元
|
| | | | 4.6932 | | | | | | 4.8768 | | | | | | 4.7850 | | | | | | 4.9246 | | |
类别
|
| |
预计使用寿命
|
|
厂房和建筑 | | | 6 - 20年 | |
机械设备 | | | 5年 - 10年 | |
家具和固定装置 | | | 3年 - 7年 | |
机动车辆 | | | 4 - 5年 | |
租赁改进 | | | 资产的租赁期限或寿命较短 | |
| | |
截至2022年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商A
|
| | | | 35,172,250 | | | | | $ | 5,540,508 | | | | | | 20.9% | | |
供应商B
|
| | | | 16,227,146 | | | | | | 2,556,181 | | | | | | 9.6% | | |
供应商C
|
| | | | 9,995,189 | | | | | | 1,574,492 | | | | | $ | 5.9% | | |
供应商D
|
| | | | 7,426,500 | | | | | | 1,169,859 | | | | | | 4.4% | | |
供应商E
|
| | | | 6,621,300 | | | | | | 1,043,020 | | | | | | 3.9% | | |
合计 | | | | | 75,442,385 | | | | | $ | 11,884,060 | | | | | | 44.7% | | |
| | |
截至2021年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商A
|
| | | | 32,063,500 | | | | | $ | 4,879,324 | | | | | | 37.9% | | |
供应商F
|
| | | | 5,781,888 | | | | | | 879,870 | | | | | | 6.8% | | |
供应商G
|
| | | | 4,862,320 | | | | | | 739,933 | | | | | $ | 5.7% | | |
供应商C
|
| | | | 4,568,088 | | | | | | 695,157 | | | | | | 5.4% | | |
供应商H
|
| | | | 3,199,200 | | | | | | 486,844 | | | | | | 3.8% | | |
合计 | | | | | 50,474,996 | | | | | $ | 7,681,128 | | | | | | 59.6% | | |
| | |
截至2022年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商E
|
| | | | 1,420,549 | | | | | $ | 223,772 | | | | | | 4.6% | | |
合计 | | | | | 1,420,549 | | | | | $ | 223,772 | | | | | | 4.6% | | |
| | |
截至2021年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商A
|
| | | | 1,225,510 | | | | | $ | 186,494 | | | | | | 8.3% | | |
合计 | | | | | 1,225,510 | | | | | $ | 186,494 | | | | | | 8.3% | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
贸易应收账款
|
| | | | 223,033,688 | | | | | | 322,170,980 | | | | | $ | 50,749,973 | | |
坏账准备
|
| | | | (8,530,951) | | | | | | (13,615,875) | | | | | | (2,144,840) | | |
应收账款净额
|
| | | | 214,502,737 | | | | | | 308,555,105 | | | | | $ | 48,605,133 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
年初余额
|
| | | | 2,116,317 | | | | | | 8,530,951 | | | | | $ | 1,343,838 | | |
添加内容
|
| | | | 6,414,634 | | | | | | 5,084,924 | | | | | | 801,002 | | |
年终余额
|
| | | | 8,530,951 | | | | | | 13,615,875 | | | | | $ | 2,144,840 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
原材料
|
| | | | 20,865,093 | | | | | | 57,926,980 | | | | | $ | 9,124,946 | | |
正在进行的工作
|
| | | | 23,453,665 | | | | | | 40,795,744 | | | | | | 6,426,348 | | |
成品
|
| | | | 78,422,922 | | | | | | 73,285,870 | | | | | | 11,544,354 | | |
对移动缓慢或陈旧的库存进行备抵
|
| | | | (41,301,797) | | | | | | (5,503,029) | | | | | | (866,864) | | |
库存,净额
|
| | | | 81,439,883 | | | | | | 166,505,565 | | | | | $ | 26,228,784 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
年初余额
|
| | | | 76,661,332 | | | | | | 41,301,797 | | | | | $ | 6,506,064 | | |
添加内容
|
| | | | 950,261 | | | | | | 4,393,629 | | | | | | 692,106 | | |
存货已核销
|
| | | | (36,309,796) | | | | | | (40,192,397) | | | | | | (6,331,306) | | |
年终余额
|
| | | | 41,301,797 | | | | | | 5,503,029 | | | | | $ | 866,864 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
成本 | | | | | | | | | | | | | | | | | | | |
施工中
|
| | | | 40,158,349 | | | | | | 318,000,074 | | | | |
$
|
50,092,951
|
| |
厂房和建筑物
|
| | | | 153,845,452 | | | | | | 170,206,987 | | | | | | 26,811,850 | | |
机械设备
|
| | | | 174,933,799 | | | | | | 194,875,303 | | | | | | 30,697,726 | | |
电子设备
|
| | | | 8,442,743 | | | | | | 10,107,578 | | | | | | 1,592,196 | | |
机动车辆
|
| | | | 2,814,066 | | | | | | 2,978,155 | | | | | | 469,134 | | |
办公设备和家具
|
| | | | 14,241,207 | | | | | | 29,888,526 | | | | | | 4,708,189 | | |
租赁改进
|
| | | | 3,889,957 | | | | | | 4,390,980 | | | | | | 691,689 | | |
总成本
|
| | | | 398,325,573 | | | | | | 730,447,603 | | | | | | 115,063,735 | | |
减去:累计折旧
|
| | | | (132,228,718) | | | | | | (150,402,597) | | | | | | (23,692,164) | | |
减值:资产减值
|
| | | | (29,891,896) | | | | | | (29,891,896) | | | | | | (4,708,720) | | |
财产和设备,净额
|
| | | | 236,204,959 | | | | | | 550,153,110 | | | | | $ | 86,662,851 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
应收贷款(1)
|
| | | | 2,966,778 | | | | | | — | | | | | $ | — | | |
存款(2) | | | | | 1,362,270 | | | | | | 2,807,847 | | | | | | 442,306 | | |
员工晋升(3)
|
| | | | 290,024 | | | | | | 383,251 | | | | | | 60,372 | | |
员工社会保障(4)
|
| | | | 190,253 | | | | | | 615,581 | | | | | | 96,969 | | |
可退还的增值税(5)
|
| | | | 148,705 | | | | | | 3,442,733 | | | | | | 542,316 | | |
其他应收账款(6)
|
| | | | 414,898 | | | | | | 854,245 | | | | | | 134,564 | | |
津贴(7) | | | | | (115,743) | | | | | | (115,743) | | | | | | (18,232) | | |
合计 | | | | | 5,257,185 | | | | | | 7,987,914 | | | | | $ | 1,258,295 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
成本 | | | | | | | | | | | | | | | | | | | |
专利
|
| | | | 79,608,000 | | | | | | 79,608,000 | | | | |
$
|
12,540,248
|
| |
许可证、软件和实验室信息系统
|
| | | | 2,526,272 | | | | | | 6,143,880 | | | | | | 967,814 | | |
土地使用权
|
| | | | 67,181,860 | | | | | | 67,181,860 | | | | | | 10,582,820 | | |
总成本
|
| | | | 149,316,132 | | | | | | 152,933,740 | | | | | | 24,090,882 | | |
减去:累计摊销
|
| | | | (65,537,529) | | | | | | (72,215,762) | | | | | | (11,375,785) | | |
无形资产净值
|
| | | | 83,778,603 | | | | | | 80,717,978 | | | | | $ | 12,715,097 | | |
| | |
截至3月31日
|
| | | | | | | | | | |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
到期日
|
| |
利率
|
| ||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| | | | | | | | | | |||||||||
中国广发银行股份有限公司 - 沈阳分行(1)
|
| | | | — | | | | | | 46,456,142 | | | | | | 7,318,002 | | | | 2022/9/16 – 2022/12/16 | | | | | 5.66% | | |
上海浦东发展银行股份有限公司沈阳分行(2)
|
| | | | — | | | | | | 64,647,870 | | | | | | 10,183,654 | | | | 2022/7/19 – 2022/12/1 | | | | | 5.30% | | |
花旗银行(3)
|
| | | | — | | | | | | 234,743 | | | | | | 36,978 | | | | 2022/5/1 | | | | | 1.00% | | |
R-Bridge Healthcare Fund,LP(4)
|
| | | | — | | | | | | 394,999 | | | | | | 62,222 | | | | 2026/9/15 | | | | | 4.00% | | |
一年内到期的银行贷款
|
| | | | — | | | | | | 111,733,754 | | | | | | 17,600,856 | | | | | | | | | | | |
花旗银行(3)
|
| | | | 1,103,609 | | | | | | — | | | | | | — | | | | 2022/5/1 | | | | | 1.00% | | |
R-Bridge Healthcare Fund,LP(4)
|
| | | | — | | | | | | 253,928,000 | | | | | | 40,000,000 | | | | 2026/9/15 | | | | | 4.00% | | |
长期银行贷款
|
| | | | 1,103,609) | | | | | | 253,928,000 | | | | | | 40,000,000 | | | | | | | | | | | |
银行贷款总额
|
| | | | 1,103,609 | | | | | | 365,661,754 | | | | | | 57,600,856 | | | | | | | | | | | |
还款日
|
| |
分期付款
|
|
2025年4月7日
|
| |
US$ 6,400,000
|
|
2025年7月7日
|
| |
6,400,000
|
|
2025年10月7日
|
| |
6,400,000
|
|
2026年1月7日
|
| |
6,400,000
|
|
2026年4月7日
|
| |
6,400,000
|
|
2026年7月7日
|
| |
8,000,000
|
|
合计 | | |
40,000,000美元
|
|
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
经营租赁ROU资产
|
| | | | 17,245,924 | | | | | | 14,850,283 | | | | | $ | 2,339,290 | | |
经营租赁负债 - 流动
|
| | | | 3,785,642 | | | | | | 4,322,252 | | | | | | 680,863 | | |
经营性租赁负债 - 非流动
|
| | | | 13,550,359 | | | | | | 10,605,260 | | | | | $ | 1,670,593 | | |
加权平均剩余租期
|
| | | | 4.4 | | | | | | 3.4 | | | | | | 3.4 | | |
加权平均贴现率
|
| | | | 5.0% | | | | | | 4.8% | | | | | | 4.8% | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
运营租赁成本
|
| | | | 2,643,917 | | | | | | 4,594,967 | | | | | $ | 723,822 | | |
经营租赁支付的现金
|
| | | | 2,601,625 | | | | | | 4,587,894 | | | | | $ | 722,708 | | |
截至2009年3月31日的财政年度
|
| |
截至2022年3月31日
|
| |||||||||
| | |
(人民币)
|
| |
(美元)
|
| ||||||
2023
|
| | | | 4,947,481 | | | | | $ | 779,352 | | |
2024
|
| | | | 4,837,260 | | | | | | 761,989 | | |
2025
|
| | | | 4,922,251 | | | | | | 775,377 | | |
2026
|
| | | | 1,479,661 | | | | | | 233,084 | | |
2027年及以后
|
| | | | — | | | | | | — | | |
租赁支付总额
|
| | | | 16,186,653 | | | | | | 2,549,802 | | |
少:利息
|
| | | | (1,259,141) | | | | | | (198,346) | | |
经营租赁负债现值
|
| | | | 14,927,512 | | | | | $ | 2,351,456 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
应付工资和社会保险(1)
|
| | | | 86,818,418 | | | | | | 57,459,273 | | | | | $ | 9,051,270 | | |
促销服务费(2)
|
| | | | 58,358,838 | | | | | | 64,883,477 | | | | | | 10,220,768 | | |
所得税以外的税
|
| | | | 1,615,475 | | | | | | 1,171,381 | | | | | | 184,522 | | |
滞纳金(3)
|
| | | | 93,890,390 | | | | | | 9,499,595 | | | | | | 1,496,423 | | |
物业、厂房和设备的应付费用
|
| | | | 4,730,933 | | | | | | 48,774,134 | | | | | | 7,683,144 | | |
疾控中心运存费用
|
| | | | 12,087,830 | | | | | | 35,023,095 | | | | | | 5,517,012 | | |
保证金(4)
|
| | | | 48,732,986 | | | | | | 94,528,659 | | | | | | 14,890,624 | | |
专业服务费(5)
|
| | | | 8,694,317 | | | | | | 7,758,448 | | | | | | 1,222,149 | | |
其他应付(6)
|
| | | | 7,821,284 | | | | | | 7,653,291 | | | | | | 1,205,584 | | |
合计 | | | | | 322,750,471 | | | | | | 326,751,353 | | | | | | 51,471,496 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
工资
|
| | | | 46,263,007 | | | | | | 49,020,045 | | | | | | 7,721,881 | | |
社会保障保险
|
| | | | 39,926,173 | | | | | | 7,732,161 | | | | | | 1,218,008 | | |
工会费
|
| | | | 629,238 | | | | | | 707,067 | | | | | | 111,381 | | |
合计 | | | | | 86,818,418 | | | | | | 57,459,273 | | | | | | 9,051,270 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
所得税滞纳金
|
| | | | 53,890,577 | | | | | | — | | | | | | — | | |
所得税以外税种的滞纳金
|
| | | | 10,635,413 | | | | | | — | | | | | | — | | |
社会保险滞纳金
|
| | | | 29,364,400 | | | | | | 9,499,595 | | | | | | 1,496,423 | | |
合计 | | | | | 93,890,390 | | | | | | 9,499,595 | | | | | | 1,496,423 | | |
| | |
系列A
|
| |
系列A-1
|
| |
系列B
|
| |
合计
|
| |
合计
|
| |||||||||||||||||||||||||||||||||
| | |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
携带
值 |
| |
携带
值 |
| ||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||||||||
截至2020年3月31日
|
| | | | 21,548,589 | | | | | | 440,585,213 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 440,585,213 | | | | | $ | 69,403,171 | | |
可转换票据的转换
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,393,610 | | | | | | 131,425,527 | | | | |
|
131,425,527
|
| | | |
|
20,702,802
|
| |
可兑换项下的看涨期权
备注 |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,660,324 | | | | | | 131,425,290 | | | | |
|
131,425,290
|
| | | |
|
20,702,765
|
| |
新保险
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,360,924 | | | | | | 597,987,709 | | | | |
|
597,987,709
|
| | | |
|
94,197,995
|
| |
股份转让
|
| | | | (6,014,313) | | | | | | (68,232,451) | | | | | | 6,014,313 | | | | | | 68,232,451 | | | | | | — | | | | | | — | | | | |
|
—
|
| | | |
|
—
|
| |
增值为赎回
值 |
| | | | — | | | | | | 1,758,690 | | | | | | — | | | | | | — | | | | | | — | | | | | | 14,851,607 | | | | |
|
16,610,297
|
| | | |
|
2,616,536
|
| |
外币折算调整
|
| | | | — | | | | | | (29,449,559) | | | | | | — | | | | | | (2,567,136) | | | | | | — | | | | | | (558,770) | | | | |
|
(32,575,465)
|
| | | |
|
(5,131,449)
|
| |
截至2021年3月31日
|
| | | | 15,534,276 | | | | | | 344,661,893 | | | | | | 6,014,313 | | | | | | 65,665,315 | | | | | | 65,414,858 | | | | | | 875,131,363 | | | | | | 1,285,458,571 | | | | | $ | 202,491,820 | | |
增加到赎回价值
|
| | | | — | | | | | | 57,598,340 | | | | | | — | | | | | | 5,164,090 | | | | | | — | | | | | | 67,899,896 | | | | |
|
130,662,326
|
| | | |
|
20,582,579
|
| |
外币折算调整
|
| | | | — | | | | | | (12,696,574) | | | | | | — | | | | | | (2,318,596) | | | | | | — | | | | | | (30,884,335) | | | | |
|
(45,899,505)
|
| | | |
|
(7,230,318)
|
| |
截至2022年3月31日
|
| | | | 15,534,276 | | | | | | 389,563,659 | | | | | | 6,014,313 | | | | | | 68,510,809 | | | | | | 65,414,858 | | | | | | 912,146,924 | | | | | | 1,370,221,392 | | | | | $ | 215,844,081 | | |
| | |
共享数量
选项 |
| |
平均运动量
每股价格 选项 |
| ||||||
| | | | | | | | |
(人民币)
|
| |||
2020年3月31日
|
| | | | 11,223,795 | | | | | | 3.8807 | | |
在此期间发放的许可证
|
| | | | 10,254,198 | | | | | | 8.4631 | | |
在此期间被没收
|
| | | | (298,117) | | | | | | 6.4631 | | |
在此期间进行锻炼
|
| | | | (8,103,671) | | | | | | — | | |
在此期间过期
|
| | | | (62,783) | | | | | | 6.4631 | | |
2021年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
在此期间发放的许可证
|
| | | | — | | | | | | — | | |
在此期间被没收
|
| | | | — | | | | | | — | | |
在此期间进行锻炼
|
| | | | — | | | | | | — | | |
在此期间过期
|
| | | | — | | | | | | — | | |
2022年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
年终了
2021年3月31日 数量: 选项 |
| |
行权价
|
| |
锻炼周期
|
|
| | |
(人民币)
|
| | | |
6,133,005
|
| |
3.4845
|
| |
2021 – 2031
|
|
2,453,049
|
| |
6.4631
|
| |
2021 – 2026
|
|
4,427,368
|
| |
13.1344
|
| |
2021 – 2026
|
|
13,013,422
|
| | | | | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
研发费用
|
| | | | 4,200,464 | | | | | | 975,171 | | | | | $ | 153,614 | | |
一般和行政费用
|
| | | | 72,501,943 | | | | | | 6,789,277 | | | | | | 1,069,481 | | |
销售费用
|
| | | | 54,093 | | | | | | — | | | | | | — | | |
股票薪酬总额
|
| | | | 76,756,500 | | | | | | 7,764,448 | | | | | $ | 1,223,094 | | |
关联方名称
|
| |
与YS集团的关系
|
|
益生生物医药有限公司 | | |
张控制的实体
|
|
益生生物医药控股有限公司 | | |
张控制的实体
|
|
开封市益盛泛亚科技有限公司 | | |
张控制的实体
|
|
北京亿盛兴业科技有限公司 | | |
张控制的实体
|
|
长春百隆生物科技有限公司 | | |
张控制的实体
|
|
河南益生汇中健康服务有限公司 | | |
张控制的实体
|
|
河南益生生物制药有限公司 | | |
张控制的实体
|
|
关联方名称
|
| |
与YS集团的关系
|
|
北京华尔盾康启生物科技有限公司 | | |
张控制的实体
|
|
辽宁益生泛亚 | | |
张控制的实体
|
|
张 | | |
董事会主席
|
|
辉少 | | | 首席执行官 | |
中开实* | | | 首席医疗官 | |
张南鹏 | | | 董事长的女儿 | |
张旭 | | | 董事长的女儿 | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股有限公司(香港)
|
| | | | 30,088,833 | | | | | | — | | | | | $ | — | | |
| | | | | 30,088,833 | | | | | | — | | | | | $ | — | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股(香港)有限公司 | | | | | | | | | | | | | | | | | | | |
YS集团代收应收账款
|
| | | | 30,088,833 | | | | | | 2,966,777 | | | | | $ | 459,412 | | |
还款给YS集团
|
| | | | | | | | | | 33,055,610 | | | | | $ | 5,118,732 | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
当期所得税
|
| | | | — | | | | | | — | | | | | $ | — | | |
递延税金
|
| | | | 17,454,245 | | | | | | 4,937,122 | | | | | | 777,720 | | |
所得税
|
| | | | 17,454,245 | | | | | | 4,937,122 | | | | | $ | 777,720 | | |
| | |
截至2009年3月31日的年度
|
| |||||||||
| | |
2021
|
| |
2022
|
| ||||||
中华人民共和国法定所得税率
|
| | | | 25.00% | | | | | | 25.00% | | |
不同司法管辖区不同税率的影响
|
| | | | (20.56)% | | | | | | (18.26)% | | |
中华人民共和国优惠税率的效果
|
| | | | (0.77)% | | | | | | 4.56% | | |
研发费用扣除等影响
|
| | | | 7.8% | | | | | | 33.2% | | |
暂时性差异*
|
| | | | 10.01% | | | | | | 4.88% | | |
估值免税额变动
|
| | | | (11.49)% | | | | | | (44.47)% | | |
实际税率
|
| | | | 10.01% | | | | | | 4.88% | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
递延税金资产: | | | | | | | | | | | | | | | | | | | |
将存货减记为可变现净值
|
| | | | 6,195,269 | | | | | | 825,454 | | | | | $ | 130,030 | | |
财产、厂房和建筑物减值
|
| | | | 2,293,516 | | | | | | 2,031,460 | | | | | | 320,006 | | |
延期政府拨款
|
| | | | 4,950,884 | | | | | | 4,852,383 | | | | | | 764,371 | | |
可用于抵销未来应税利润的亏损
|
| | | | 32,495,322 | | | | | | 58,257,270 | | | | | | 9,176,975 | | |
减去:估值免税额
|
| | | | (32,495,322) | | | | | | (58,257,270) | | | | | | (9,176,975) | | |
递延税金资产总额,净额
|
| | | | 13,439,669 | | | | | | 7,709,297 | | | | | | 1,214,407 | | |
递延纳税义务: | | | | | | | | | | | | | | | | | | | |
因历史收购子公司而产生的公允价值调整
|
| | | | (5,463,463) | | | | | | (4,670,213) | | | | | | (735,675) | | |
递延纳税负债总额
|
| | | | (5,463,463) | | | | | | (4,670,213) | | | | | | (735,675) | | |
递延税金净资产
|
| | | | 7,976,206 | | | | | | 3,039,084 | | | | | $ | 478,732 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
政府对财产、厂房和设备的补助 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 21,096,442 | | | | | | 21,847,340 | | | | | $ | 3,441,502 | | |
添加
|
| | | | 2,000,000 | | | | | | 1,552,000 | | | | | | 244,479 | | |
确认为收入
|
| | | | (1,249,102) | | | | | | (1,368,650) | | | | | | (215,597) | | |
小计 | | | | | 21,847,340 | | | | | | 22,030,690 | | | | | $ | 3,470,384 | | |
政府用于研发的拨款 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 10,387,874 | | | | | | 11,158,551 | | | | | $ | 1,757,750 | | |
添加
|
| | | | 1,610,700 | | | | | | — | | | | | | — | | |
确认为收入
|
| | | | (840,023) | | | | | | (840,023) | | | | | | (132,325) | | |
小计 | | | | | 11,158,551 | | | | | | 10,318,528 | | | | | $ | 1,625,425 | | |
递延政府拨款总额
|
| | | | 33,005,891 | | | | | | 32,349,218 | | | | | $ | 5,095,809 | | |
少:当前部分
|
| | | | (2,121,645) | | | | | | (2,295,701) | | | | | | (361,630) | | |
非当前部分
|
| | | | 30,884,246 | | | | | | 30,053,517 | | | | | $ | 4,734,179 | | |
| | |
截至3月31日
|
| |||||||||
| | |
2022
|
| |
2022
|
| ||||||
| | |
(人民币)
|
| |
(美元)
|
| ||||||
其他专业服务费
|
| | | | 7,617,840 | | | | | $ | 1,200,000 | | |
研发
|
| | | | 73,894,705 | | | | | | 11,640,261 | | |
采购原材料
|
| | | | 17,664,500 | | | | | | 17,664,500 | | |
合计 | | | | | 99,177,045 | | | | | $ | 30,504,761 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
中华人民共和国
|
| | | | 288,637,839 | | | | | | 604,094,049 | | | | | $ | 95,159,896 | | |
其他国家/地区
|
| | | | 31,345,723 | | | | | | 26,777,039 | | | | | $ | 4,218,052 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 330,296,949 | | | | | | 252,611,535 | | | | |
$
|
39,792,624
|
| |
关联方应付金额
|
| | | | 495,937,171 | | | | | | 519,236,876 | | | | | | 81,792,772 | | |
流动资产总额
|
| | | | 826,234,120 | | | | | | 771,848,411 | | | | | | 121,585,396 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
长期投资,净额
|
| | | | 150,952,826 | | | | | | 146,641,652 | | | | | | 23,099,721 | | |
非流动资产合计
|
| | | | 150,952,826 | | | | | | 146,641,652 | | | | | | 23,099,721 | | |
总资产
|
| | | | 977,186,946 | | | | | | 918,490,063 | | | | | $ | 144,685,117 | | |
负债和权益 | | | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
应计费用和其他负债
|
| | | | 197,324,794 | | | | | | 244,082,463 | | | | |
$
|
38,449,082
|
| |
应付关联方金额
|
| | | | 3,266,288 | | | | | | 3,155,395 | | | | | | 497,053 | | |
流动负债总额
|
| | | | 200,591,082 | | | | | | 247,237,858 | | | | | | 38,946,135 | | |
总负债
|
| | | | 200,591,082 | | | | | | 247,237,858 | | | | | | 38,946,135 | | |
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;截至2022年和2021年3月31日已发行和已发行的21,548,589股)
|
| | | | 410,327,208 | | | | | | 458,074,468 | | | | | | 72,158,166 | | |
B系列可赎回可转换优先股(面值
每股价值0.000005美元,100,000,000股 授权;已发行65,414,858股, 截至2022年3月31日和2021年3月31日的未偿还债务) |
| | | | 875,131,363 | | | | | | 912,146,924 | | | | | | 143,685,915 | | |
夹层总股本
|
| | | | 1,285,458,571 | | | | | | 1,370,221,392 | | | | | | 215,844,081 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
股东亏损: | | | | | | | | | | | | | | | | | | | |
普通股,每股票面价值0.000005美元,授权股份99.5亿股,2022年和2021年3月31日已发行和已发行股票247,311,533股*
|
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,257 | | |
新增实收资本
|
| | | | 800,806,378 | | | | | | 808,502,018 | | | | | | 127,359,254 | | |
留存收益
|
| | | | (1,353,900,436) | | | | | | (1,590,567,163) | | | | | | (250,554,041) | | |
累计其他综合收益
|
| | | | 44,223,373 | | | | | | 83,087,980 | | | | | | 13,088,431 | | |
股东亏损总额
|
| | | | (508,862,707) | | | | | | (698,969,187) | | | | | | (110,105,099) | | |
总负债、夹层权益和股东亏损
|
| | | | 977,186,946 | | | | | | 918,490,063 | | | | | $ | 144,685,117 | | |
|
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
子公司股权损失
|
| | | | (60,903,713) | | | | | | (75,864,722) | | | | | $ | (11,950,588) | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售费用
|
| | | | 54,278 | | | | | | — | | | | | | — | | |
一般和行政费用
|
| | | | 104,562,058 | | | | | | 29,178,255 | | | | | | 4,596,304 | | |
研发费用
|
| | | | 4,352,356 | | | | | | 988,531 | | | | | | 155,718 | | |
总运营费用
|
| | | | 108,968,692 | | | | | | 30,166,786 | | | | | | 4,752,022 | | |
运营亏损
|
| | | | (169,872,405) | | | | | | (106,031,508) | | | | | | (16,702,610) | | |
其他收入(支出) | | | | | |||||||||||||||
财务收入/(支出),净额
|
| | | | (21,953,837) | | | | | | 27,107 | | | | | | 4,270 | | |
其他收入/(支出)合计,净额
|
| | | | (21,953,837) | | | | | | 27,107 | | | | | | 4,270 | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (16,610,297) | | | | | | (130,662,326) | | | | | | (20,582,579) | | |
可归因于YS Biophma的净亏损
|
| | | | (208,436,538) | | | | | | (236,666,727) | | | | | | (37,280,919) | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
伪造货币兑换收益
|
| | | | 22,455,217 | | | | | | 38,864,607 | | | | | | 6,122,146 | | |
全面亏损
|
| | | | (169,371,025) | | | | | | (67,139,794) | | | | | $ | (10,576,194) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.78) | | | | | | (0.43) | | | | | $ | (0.07) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | $ | (16,698,340) | | |
子公司股权损失
|
| | | | 60,903,713 | | | | | | 75,864,722 | | | | | | 11,950,588 | | |
基于股份的薪酬
|
| | | | 76,756,500 | | | | | | 7,764,448 | | | | | | 1,223,094 | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
关联方应付金额
|
| | | | (421,125,633) | | | | | | (23,299,705) | | | | | | (3,670,285) | | |
应付关联方金额
|
| | | | 2,906,881 | | | | | | (110,893) | | | | | | (17,468) | | |
应计费用和其他负债
|
| | | | 77,228,629 | | | | | | (24,732,348) | | | | | | (3,895,962) | | |
经营活动中使用的净现金
|
| | | | (395,156,152) | | | | | | (70,518,177) | | | | | | (11,108,373) | | |
投资活动现金流: | | | | | | | | | | | | | | | | | | | |
支付长期投资费用
|
| | | | (7,658,738) | | | | | | (813,776) | | | | | | (128,190) | | |
投资活动中使用的净现金
|
| | | | (7,658,738) | | | | | | (813,776) | | | | | | (128,190) | | |
融资活动的现金流:
|
| | | | | | | | | | | | | | | | | | |
发行夹层股权所得收益
|
| | | | 729,412,999 | | | | | | — | | | | | | — | | |
股东出资
|
| | | | 1,589,236 | | | | | | — | | | | | | — | | |
融资活动提供的现金净额
|
| | | | 731,002,235 | | | | | | — | | | | | | — | | |
汇率对现金的影响
|
| | | | 2,109,604 | | | | | | (6,353,461) | | | | | | (1,000,829) | | |
现金净(减)增
|
| | | | 330,296,949 | | | | | | (77,685,414) | | | | | | (12,237,392) | | |
年初现金
|
| | | | — | | | | | | 330,296,949 | | | | | | 52,030,016 | | |
年终现金
|
| | | | 330,296,949 | | | | | | 252,611,535 | | | | | $ | 39,792,624 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 16,610,297 | | | | | | 130,662,326 | | | | | $ | 20,582,579 | | |
关联方的宽恕
|
| | | | 446,092,527 | | | | | | — | | | | | $ | — | | |
| | |
3月31日
2022 |
| |
9月30日
2022 |
| |
9月30日
2022 |
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 271,067,503 | | | | | | 226,765,500 | | | | | $ | 31,939,703 | | |
受限现金
|
| | | | — | | | | | | 261,766 | | | | | | 36,869 | | |
应收账款净额
|
| | | | 308,555,105 | | | | | | 468,359,388 | | | | | | 65,967,969 | | |
预付款给供应商
|
| | | | 10,648,306 | | | | | | 7,556,142 | | | | | | 1,064,275 | | |
库存,净额
|
| | | | 166,505,565 | | | | | | 161,667,187 | | | | | | 22,770,668 | | |
预付费用和其他流动资产
|
| | | | 7,987,914 | | | | | | 6,942,700 | | | | | | 977,873 | | |
流动资产总额
|
| | | | 764,764,393 | | | | | | 871,552,683 | | | | | | 122,757,357 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备,净额
|
| | | | 550,153,110 | | | | | | 557,366,853 | | | | | | 78,504,585 | | |
经营性租赁使用权资产,净额
|
| | | | 14,850,283 | | | | | | 13,067,129 | | | | | | 1,840,493 | | |
递延税金资产净额
|
| | | | 3,039,084 | | | | | | 2,473,459 | | | | | | 348,384 | | |
无形资产净值
|
| | | | 80,717,978 | | | | | | 81,314,933 | | | | | | 11,453,130 | | |
其他非流动资产
|
| | | | 28,228,293 | | | | | | 22,663,063 | | | | | | 3,192,071 | | |
非流动资产合计
|
| | | | 676,988,748 | | | | | | 676,885,437 | | | | | | 95,338,663 | | |
总资产
|
| | | | 1,441,753,141 | | | | | | 1,548,438,120 | | | | | $ | 218,096,020 | | |
负债、夹层股权和股东亏损
|
| | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - Current
|
| | | | 111,733,754 | | | | | | 163,641,078 | | | | | $ | 23,048,688 | | |
应付账款
|
| | | | 30,811,100 | | | | | | 37,394,178 | | | | | | 5,266,934 | | |
应计费用和其他负债
|
| | | | 326,751,353 | | | | | | 367,283,321 | | | | | | 51,731,502 | | |
经营租赁负债 - 流动
|
| | | | 4,322,252 | | | | | | 3,524,558 | | | | | | 496,431 | | |
延期政府拨款 - Current
|
| | | | 2,295,701 | | | | | | 3,495,701 | | | | | | 492,366 | | |
流动负债总额
|
| | | | 475,914,160 | | | | | | 575,338,836 | | | | | | 81,035,921 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - 非流动
|
| | | | 253,928,000 | | | | | | 283,992,000 | | | | | | 40,000,000 | | |
经营性租赁负债 - 非流动
|
| | | | 10,605,260 | | | | | | 10,403,843 | | | | | | 1,465,371 | | |
延期政府拨款 - 非当前
|
| | | | 30,053,517 | | | | | | 20,826,966 | | | | | | 2,933,458 | | |
非流动负债合计
|
| | | | 294,586,777 | | | | | | 315,222,809 | | | | | | 44,398,829 | | |
总负债
|
| | | | 770,500,937 | | | | | | 890,561,645 | | | | | | 125,434,750 | | |
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;已发行和已发行21,548,589股)
|
| | | | 458,074,468 | | | | | | 551,004,725 | | | | | | 77,608,485 | | |
B系列可赎回可转换优先股(每股面值0.000005美元
股份,授权发行100,000,000股;已发行65,414,858股, 未完成) |
| | | | 912,146,924 | | | | | | 1,057,557,002 | | | | | | 148,955,886 | | |
夹层总股本
|
| | | | 1,370,221,392 | | | | | | 1,608,561,727 | | | | | | 226,564,371 | | |
承付款和或有事项
|
| | | | — | | | | | | — | | | | | | — | | |
股东亏损 | | | | | | | | | | | | | | | | | | | |
普通股,每股票面价值0.000005美元,99.5亿股
截至3月31日,已发行和已发行股票247,311,533股 截至2022年9月30日,已发行和已发行股票246,736,533股 2022.* |
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,124 | | |
新增实收资本
|
| | | | 808,502,018 | | | | | | 808,648,509 | | | | | | 113,897,365 | | |
累计亏损
|
| | | | (1,590,567,163) | | | | | | (1,673,775,766) | | | | | | (235,749,706) | | |
累计其他综合收益(亏损)
|
| | | | 83,087,979 | | | | | | (85,565,973) | | | | | | (12,051,884) | | |
股东亏损总额
|
| | | | (698,969,188) | | | | | | (950,685,252) | | | | | | (133,903,101) | | |
总负债、夹层权益和股东亏损
|
| | | | 1,441,753,141 | | | | | | 1,548,438,120 | | | | | $ | 218,096,020 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
收入 | | | | | 269,433,426 | | | | | | 399,534,723 | | | | | $ | 56,274,081 | | |
收入成本
|
| | | | 63,599,621 | | | | | | 93,700,779 | | | | | | 13,197,665 | | |
毛利
|
| | | | 205,833,805 | | | | | | 305,833,944 | | | | | | 43,076,416 | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | 86,265,281 | | | | | | 150,228,079 | | | | | | 21,159,480 | | |
一般和行政
|
| | | | 51,664,591 | | | | | | 49,587,013 | | | | | | 6,984,283 | | |
研发
|
| | | | 124,051,209 | | | | | | 123,861,107 | | | | | | 17,445,718 | | |
总运营费用
|
| | | | 261,981,081 | | | | | | 323,676,199 | | | | | | 45,589,481 | | |
运营亏损
|
| | | | (56,147,276) | | | | | | (17,842,255) | | | | | | (2,513,065) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | |
与所得税以外的其他税有关的滞纳金
|
| | | | (112,420) | | | | | | — | | | | | | — | | |
社保相关滞纳金
|
| | | | (1,396,221) | | | | | | (299,417) | | | | | | (42,173) | | |
政府拨款
|
| | | | 19,600,822 | | | | | | 22,456,691 | | | | | | 3,163,003 | | |
财务费用,净额
|
| | | | (352,694) | | | | | | (14,949,434) | | | | | | (2,105,613) | | |
其他(费用)收入,净额
|
| | | | (993,957) | | | | | | 74,675 | | | | | | 10,518 | | |
其他收入总额,净额
|
| | | | 16,745,530 | | | | | | 7,282,515 | | | | | | 1,025,735 | | |
所得税前亏损
|
| | | | (39,401,746) | | | | | | (10,559,740) | | | | | | (1,487,330) | | |
所得税费用
|
| | | | (5,689,586) | | | | | | (565,625) | | | | | | (79,668) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (65,013,751) | | | | | | (72,083,238) | | | | | | (10,152,855) | | |
易升生物股份有限公司净亏损
|
| | | | (110,105,083) | | | | | | (83,208,603) | | | | | $ | (11,719,853) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | $ | (1,566,998) | | |
其他综合收益(亏损):外币折算收益(亏损)
|
| | | | 11,321,167 | | | | | | (168,653,952) | | | | | | (23,754,747) | | |
全面亏损
|
| | | | (33,770,165) | | | | | | (179,779,317) | | | | | $ | (25,321,745) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.18) | | | | | | (0.05) | | | | | $ | (0.01) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,141,861 | | | | | | 247,141,861 | | |
| | |
普通股*
|
| |
额外的
实收 大写 |
| |
赤字
|
| |
累计
其他 全面 收入(亏损) |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |||||||||||||||
截至2022年3月31日的余额
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 808,502,018 | | | | | | (1,590,567,163) | | | | | | 83,087,979 | | | | | | (698,969,188) | | |
增加可转换债券的赎回价值
可赎回优先股 |
| | | | — | | | | | | — | | | | | | — | | | | | | (72,083,238) | | | | | | — | | | | |
|
(72,083,238)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (11,125,365) | | | | | | — | | | | |
|
(11,125,365)
|
| |
基于股份的薪酬
|
| | | | (575,000) | | | | | | — | | | | | | (85,316) | | | | | | — | | | | | | — | | | | |
|
(85,316)
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | 231,807 | | | | | | — | | | | | | (168,653,952) | | | | |
|
(168,422,145)
|
| |
截至2022年9月30日的余额(以人民币计)(未经审计)
|
| | | | 246,736,533 | | | | | | 7,978 | | | | | | 808,648,509 | | | | | | (1,673,775,766) | | | | | | (85,565,973) | | | | | | (950,685,252) | | |
截至2022年9月30日的余额(单位:美元)(未经审计)
|
| | | | 246,736,533 | | | | | | 1,124 | | | | | | 113,897,365 | | | | | | (235,749,706) | | | | | | (12,051,884) | | | | | | (133,903,101) | | |
| | |
普通股*
|
| |
额外的
实收 大写 |
| |
赤字
|
| |
累计
其他 全面 收入 |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |||||||||||||||
截至2021年3月31日的余额
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 800,806,378 | | | | | | (1,353,900,436) | | | | | | 44,223,373 | | | | | | (508,862,707) | | |
增加可转换债券的赎回价值
可赎回优先股 |
| | | | — | | | | | | — | | | | | | — | | | | | | (65,013,751) | | | | | | — | | | | |
|
(65,013,751)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (45,091,332) | | | | | | — | | | | |
|
(45,091,332)
|
| |
基于股份的薪酬
|
| | | | — | | | | | | — | | | | | | 3,128,741 | | | | | | — | | | | | | — | | | | |
|
3,128,741
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,321,167 | | | | |
|
11,321,167
|
| |
截至2021年9月30日的余额(单位:人民币)
(未经审计) |
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 803,935,119 | | | | | | (1,464,005,519) | | | | | | 55,544,540 | | | | | | (604,517,882) | | |
截至2021年9月30日的余额(单位:美元)(未经审计)
|
| | | | 247,311,533 | | | | | | 1,124 | | | | | | 113,233,488 | | | | | | (206,203,769) | | | | | | 7,823,395 | | | | | | (85,145,762) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
经营活动现金流: | | | | | | | | | | | | | | | | | | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | $ | (1,566,997) | | |
将净亏损与经营活动中使用的现金净额进行调整:
|
| | | | | | | | | | | | | | | | | | |
递延所得税
|
| | | | 5,689,586 | | | | | | 565,625 | | | | | | 79,668 | | |
财产、厂房和设备折旧
|
| | | | 11,560,041 | | | | | | 13,818,386 | | | | | | 1,946,306 | | |
无形资产摊销
|
| | | | 3,326,419 | | | | | | 3,409,643 | | | | | | 480,245 | | |
处置财产、厂房和设备的损失
|
| | | | 238,279 | | | | | | 64,179 | | | | | | 9,040 | | |
基于股份的薪酬
|
| | | | 3,128,741 | | | | | | (85,316) | | | | | | (12,017) | | |
应收账款减值
|
| | | | 2,888,417 | | | | | | 6,447,109 | | | | | | 908,069 | | |
非现金租赁费用
|
| | | | 1,805,910 | | | | | | 2,409,286 | | | | | | 339,346 | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
库存
|
| | | | (40,481,983) | | | | | | 4,838,379 | | | | | | 681,481 | | |
应收账款
|
| | | | (96,243,492) | | | | | | (166,251,393) | | | | | | (23,416,349) | | |
关联方应付金额
|
| | | | 30,088,833 | | | | | | | | | | | | | | |
预付费用和其他流动资产
|
| | | | (31,314,821) | | | | | | 4,102,924 | | | | | | 577,893 | | |
应付账款
|
| | | | 16,697,346 | | | | | | 6,583,078 | | | | | | 927,220 | | |
应计费用和其他负债
|
| | | | (37,906,402) | | | | | | 37,289,942 | | | | | | 5,252,252 | | |
延期政府拨款
|
| | | | 491,177 | | | | | | (8,026,551) | | | | | | (1,130,532) | | |
经营性租赁负债
|
| | | | (1,861,093) | | | | | | (1,435,079) | | | | | | (202,129) | | |
经营活动中使用的净现金
|
| | | | (176,984,374) | | | | | | (107,395,153) | | | | | | (15,126,504) | | |
投资活动现金流: | | | | | | | | | | | | | | | | | | | |
处置财产、厂房和设备所得收益
|
| | | | 8,000 | | | | | | — | | | | | | — | | |
购置房产、厂房和设备
|
| | | | (202,828,177) | | | | | | (15,017,753) | | | | | | (2,115,236) | | |
购买无形资产
|
| | | | (570,200) | | | | | | (4,006,598) | | | | | | (564,325) | | |
投资活动中使用的净现金
|
| | | | (203,390,377) | | | | | | (19,024,351) | | | | | | (2,679,561) | | |
融资活动的现金流: | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款的收益
|
| | | | 92,719,786 | | | | | | 102,513,927 | | | | | | 14,438,988 | | |
偿还银行和其他借款
|
| | | | (48,833,921) | | | | | | (50,606,602) | | | | | | (7,127,891) | | |
融资活动提供的现金净额
|
| | | | 43,885,865 | | | | | | 51,907,325 | | | | | | 7,311,097 | | |
汇率对现金的影响
|
| | | | (4,446,301) | | | | | | 30,471,942 | | | | | | 4,291,943 | | |
现金和受限现金净减少
|
| | | | (340,935,187) | | | | | | (44,040,237) | | | | | | (6,203,025) | | |
期初现金和受限现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | | 38,179,597 | | |
期末现金和受限现金
|
| | | | 49,521,897 | | | | | | 227,027,266 | | | | | $ | 31,976,572 | | |
现金和受限现金对账 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 49,521,897 | | | | | | 226,765,500 | | | | | | 31,939,703 | | |
受限现金
|
| | | | — | | | | | | 261,766 | | | | | | 36,869 | | |
现金流量表中显示的现金总额和限制性现金
|
| | | | 49,521,897 | | | | | | 227,027,266 | | | | | | 31,976,572 | | |
现金流量信息补充披露: | | | | | | | | | | | | | | | | | | | |
已支付利息
|
| | | | 402,617 | | | | | | 12,723,051 | | | | | $ | 1,792,030 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 65,013,751 | | | | | | 72,083,238 | | | | | $ | 10,152,855 | | |
|
‘法人实体
|
| |
业务性质
|
| |
注册日期
|
| |
公司注册地
|
|
|
益生生物股份有限公司
(“YS Biophma”) |
| | 控股公司 | | |
2020年11月16日
|
| | 开曼群岛 | |
|
亿盛生物(香港)控股有限公司
(“香港益生生物”) |
| | 控股公司 | | |
2020年12月28日
|
| | 香港 | |
| [br]益生生物(新加坡)有限公司有限公司
(“新加坡益生”)* |
| | 疫苗和治疗性生物制品的研究和开发 | | |
2009年11月28日
|
| | 新加坡 | |
|
益生美国生物制药有限公司
(“美国益生”) |
| | 疫苗和治疗性生物制品的研究 | | |
2009年9月29日
|
| | 美国 | |
|
海景生物科学收购有限公司
(“海景生物科学”) |
| | 用于收购 | | | 2022年8月17日 | | | 开曼群岛 | |
|
哈德逊生物医药集团有限公司
(“哈德逊生物医学”) |
| | 用于收购 | | | 2022年8月17日 | | | 开曼群岛 | |
|
辽宁益生生物制药有限公司
(“辽宁益生”)** |
| | 疫苗和治疗性生物制品的研发、制造和商业化 | | | 1994年5月26日 | | | 中华人民共和国 | |
|
北京益生生物科技有限公司
(“北京益生”) |
| | 疫苗和治疗性生物制品的研究和开发 | | | 2021年2月4日 | | | 中华人民共和国 | |
| | |
2022年9月30日
|
| |
2022年3月31日
|
| |
截至6个月的时间
9月30日 |
| |||||||||||||||
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
外币
|
| |
资产负债表
|
| |
资产负债表
|
| |
损益
|
| |
损益
|
| ||||||||||||
人民币:1$
|
| | | | 7.0998 | | | | | | 6.3482 | | | | | | 6.7240 | | | | | | 6.5284 | | |
人民币:1美元
|
| | | | 4.9717 | | | | | | 4.6932 | | | | | | 4.8325 | | | | | | 4.8200 | | |
类别
|
| |
预计使用寿命
|
|
厂房和建筑 | | | 6 - 20年 | |
机械设备 | | | 5年 - 10年 | |
家具和固定装置 | | | 3年 - 7年 | |
机动车辆 | | | 4 - 5年 | |
租赁改进 | | | 资产的租赁期限或寿命较短 | |
| | |
截至2022年9月30日的六个月
|
| |||||||||||||||
| | |
(人民币)
|
| |
($)
|
| | | | | | | ||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
供应商A
|
| | | | 21,661,500 | | | | | $ | 3,051,001 | | | | | | 38.8% | | |
供应商B
|
| | | | 10,053,600 | | | | | | 1,416,040 | | | | | | 18.0% | | |
供应商C
|
| | | | 3,005,828 | | | | | | 423,368 | | | | | | 5.4% | | |
供应商D
|
| | | | 2,009,315 | | | | | | 283,010 | | | | | | 3.6% | | |
供应商I
|
| | | | 1,859,500 | | | | | | 261,909 | | | | | | 3.3% | | |
合计 | | | | | 38,589,743 | | | | | $ | 5,435,328 | | | | | | 69.1% | | |
| | |
截至2021年9月30日的六个月
|
| |||||||||||||||
| | |
(人民币)
|
| |
($)
|
| | | | | | | ||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
供应商A
|
| | | | 11,283,000 | | | | | $ | 1,589,200 | | | | | | 12.5% | | |
供应商F
|
| | | | 9,028,170 | | | | | | 1,271,609 | | | | | | 10.0% | | |
供应商D
|
| | | | 6,689,566 | | | | | | 942,219 | | | | | | 7.4% | | |
供应商G
|
| | | | 6,063,000 | | | | | | 853,968 | | | | | | 6.7% | | |
供应商H
|
| | | | 5,460,000 | | | | | | 769,036 | | | | | | 6.1% | | |
合计 | | | | | 38,523,736 | | | | | $ | 5,426,032 | | | | | | 42.7% | | |
| | |
计价的
币种 |
| |
2022年3月31日
|
| |
2022年9月30日
|
| ||||||||||||||||||||||||
| | |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||||||||
| | | | | | | | | | | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
中华人民共和国
|
| |
人民币
|
| | | | 1,155,124,790 | | | | | | 80% | | | | | | 1,316,093,351 | | | | | $ | 185,370,484 | | | | | | 85% | | |
香港
|
| |
$
|
| | | | 2,666,762 | | | | | | 0% | | | | | | 194,452,627 | | | | | | 27,388,465 | | | | | | 13% | | |
新加坡
|
| |
S$
|
| | | | 26,168,621 | | | | | | 2% | | | | | | 29,843,991 | | | | | | 4,203,497 | | | | | | 2% | | |
美国
|
| |
$
|
| | | | 5,181,433 | | | | | | 0% | | | | | | 4,104,976 | | | | | | 578,182 | | | | | | 0% | | |
开曼群岛
|
| |
$
|
| | | | 252,611,535 | | | | | | 18% | | | | | | 3,943,175 | | | | | | 555,392 | | | | | | 0% | | |
合计 | | | | | | | | 1,441,753,141 | | | | | | 100% | | | | | | 1,548,438,120 | | | | | $ | 218,096,020 | | | | | | 100% | | |
| | |
3月31日
2022 |
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
贸易应收账款
|
| | | | 322,170,980 | | | | | | 488,422,373 | | | | | $ | 68,793,821 | | |
坏账准备
|
| | | | (13,615,875) | | | | | | (20,062,985) | | | | | | (2,825,852) | | |
应收账款净额
|
| | | | 308,555,105 | | | | | | 468,359,388 | | | | | $ | 65,967,969 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
4月1日的余额
|
| | | | 8,530,951 | | | | | | 13,615,875 | | | | | $ | 1,917,783 | | |
添加内容
|
| | | | 2,888,417 | | | | | | 6,447,110 | | | | | | 908,069 | | |
9月30日余额
|
| | | | 11,419,368 | | | | | | 20,062,985 | | | | | $ | 2,825,852 | | |
| | |
3月31日
2022 |
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
原材料
|
| | | | 57,926,980 | | | | | | 52,392,648 | | | | | $ | 7,379,454 | | |
正在进行的工作
|
| | | | 40,795,744 | | | | | | 39,148,872 | | | | | | 5,514,081 | | |
成品
|
| | | | 73,285,870 | | | | | | 71,235,067 | | | | | | 10,033,391 | | |
对移动缓慢或陈旧的库存进行备抵
|
| | | | (5,503,029) | | | | | | (1,109,400) | | | | | | (156,258) | | |
库存,净额
|
| | | | 166,505,565 | | | | | | 161,667,187 | | | | | $ | 22,770,668 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
4月1日的余额
|
| | | | 41,301,797 | | | | | | 5,503,029 | | | | | $ | 775,096 | | |
存货已核销
|
| | | | (40,192,397) | | | | | | (4,393,629) | | | | | | (618,838) | | |
9月30日余额
|
| | | | 1,109,400 | | | | | | 1,109,400 | | | | | $ | 156,258 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
成本
|
| | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
施工中
|
| | | | 318,000,074 | | | | | | 333,446,243 | | | | | $ | 46,965,583 | | |
厂房和建筑物
|
| | | | 170,206,987 | | | | | | 183,372,813 | | | | | | 25,827,884 | | |
机械设备
|
| | | | 194,875,303 | | | | | | 193,846,868 | | | | | | 27,303,145 | | |
电子设备
|
| | | | 10,107,578 | | | | | | 10,794,907 | | | | | | 1,520,452 | | |
机动车辆
|
| | | | 2,978,155 | | | | | | 3,027,767 | | | | | | 426,458 | | |
办公设备和家具
|
| | | | 29,888,526 | | | | | | 21,612,891 | | | | | | 3,044,155 | | |
租赁改进
|
| | | | 4,390,980 | | | | | | 4,626,927 | | | | | | 651,698 | | |
总成本
|
| | | | 730,447,603 | | | | | | 750,728,416 | | | | | | 105,739,375 | | |
减去:累计折旧
|
| | | | (150,402,597) | | | | | | (163,469,667) | | | | | | (23,024,545) | | |
减值:资产减值
|
| | | | (29,891,896) | | | | | | (29,891,896) | | | | | | (4,210,245) | | |
财产和设备,净额
|
| | | | 550,153,110 | | | | | | 557,366,853 | | | | | $ | 78,504,585 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
存款(1)
|
| | | | 2,807,847 | | | | | | 1,622,616 | | | | | $ | 228,544 | | |
员工晋升(2)
|
| | | | 383,251 | | | | | | 303,767 | | | | | | 42,785 | | |
员工社保(3)
|
| | | | 615,581 | | | | | | 677,626 | | | | | | 95,443 | | |
可退还的增值税(4)
|
| | | | 3,442,733 | | | | | | 3,920,265 | | | | | | 552,166 | | |
其他应收账款(5)
|
| | | | 854,245 | | | | | | 534,169 | | | | | | 75,237 | | |
津贴(6) | | | | | (115,743) | | | | | | (115,743) | | | | | | (16,302) | | |
合计 | | | | | 7,987,914 | | | | | | 6,942,700 | | | | | $ | 977,873 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
成本 | | | | | | | | | | | | | | | | | | | |
专利
|
| | | | 79,608,000 | | | | | | 79,608,000 | | | | |
$
|
11,212,710
|
| |
许可证、软件和实验室信息系统
|
| | | | 6,143,880 | | | | | | 10,150,478 | | | | | | 1,429,685 | | |
土地使用权
|
| | | | 67,181,860 | | | | | | 67,181,860 | | | | | | 9,462,500 | | |
总成本
|
| | | | 152,933,740 | | | | | | 156,940,338 | | | | | | 22,104,895 | | |
减去:累计摊销
|
| | | | (72,215,762) | | | | | | (75,625,405) | | | | | | (10,651,765) | | |
无形资产净值
|
| | | | 80,717,978 | | | | | | 81,314,933 | | | | | $ | 11,453,130 | | |
| | |
3月31日
2022 |
| |
9月30日
2022 |
| |
9月30日
2022 |
| |
到期日
|
| |
利率
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| | | | | | | |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
中国广发银行股份有限公司 - 沈阳分行(1)
|
| | | | 46,456,142 | | | | | | 35,509,492 | | | | | $ | 5,001,478 | | | | 2022/11/17 – 2022/12/16 | | |
5.66%
|
|
上海浦东发展银行股份有限公司沈阳分行(2)
|
| | | | 64,647,870 | | | | | | 81,486,261 | | | | | | 11,477,261 | | | | 2022/10/11 – 2023/09/22 | | |
5.30%
|
|
花旗银行(3)
|
| | | | 234,743 | | | | | | — | | | | | | — | | | | 2022/5/1 | | |
1.00%
|
|
R-Bridge Healthcare Fund,LP(4)
|
| | | | 394,999 | | | | | | — | | | | | | — | | | | 2026/9/15 | | |
4.00%
|
|
中国中信股份银行 - 沈阳
分支机构(5) |
| | | | — | | | | | | 34,295,325 | | | | | | 4,830,464 | | | | 2023/3/16 – 2023/5/19 | | |
5.2% / 3.25%
|
|
中国建设银行沈阳 -
分支机构(6) |
| | | | — | | | | | | 12,350,000 | | | | | | 1,739,485 | | | |
2023/9/8 – 2023/9/27
|
| |
4.00%
|
|
一年内到期的银行贷款
|
| | | | 111,733,754 | | | | | | 163,641,078 | | | | | $ | 23,048,688 | | | | | | | | |
R-Bridge Healthcare Fund,LP(4)
|
| | | | 253,928,000 | | | | | | 283,992,000 | | | | | | 40,000,000 | | | | 2026/9/15 | | |
4.00%
|
|
长期银行贷款
|
| | | | 253,928,000 | | | | | | 283,992,000 | | | | | | 40,000,000 | | | | | | | | |
银行贷款总额
|
| | | | 365,661,754 | | | | | | 447,633,078 | | | | | $ | 63,048,688 | | | | | | | | |
还款日
|
| |
还款
分期付款 |
| |||
2025年4月7日
|
| | | $ | 6,400,000 | | |
2025年7月7日
|
| | | | 6,400,000 | | |
2025年10月7日
|
| | | | 6,400,000 | | |
2026年1月7日
|
| | | | 6,400,000 | | |
2026年4月7日
|
| | | | 6,400,000 | | |
2026年7月7日
|
| | | | 8,000,000 | | |
合计 | | | | $ | 40,000,000 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
经营租赁ROU资产
|
| | | | 14,850,283 | | | | | | 13,067,129 | | | | | $ | 1,840,493 | | |
经营租赁负债 - 流动
|
| | | | 4,322,252 | | | | | | 3,524,558 | | | | | | 496,431 | | |
经营性租赁负债 - 非流动
|
| | | | 10,605,260 | | | | | | 10,403,843 | | | | | $ | 1,465,371 | | |
加权平均剩余租期
|
| | | | 3.4 | | | | | | 3.0 | | | | | | 3.0 | | |
加权平均贴现率
|
| | | | 4.8% | | | | | | 4.8% | | | | | | 4.8% | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
运营租赁成本
|
| | | | 2,237,633 | | | | | | 2,508,388 | | | | | $ | 373,050 | | |
经营租赁支付的现金
|
| | | | 2,276,956 | | | | | | 786,888 | | | | | $ | 110,832 | | |
截至9月30日的12个月
|
| |
截至2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
($)
|
| ||||||
2023
|
| | | | 5,748,070 | | | | | $ | 809,610 | | |
2024
|
| | | | 5,029,426 | | | | | | 708,390 | | |
2025
|
| | | | 3,921,138 | | | | | | 552,289 | | |
2026
|
| | | | 158,029 | | | | | | 22,257 | | |
租赁支付总额
|
| | | | 14,856,663 | | | | | | 2,092,546 | | |
少:利息
|
| | | | (928,262) | | | | | | (130,744) | | |
经营租赁负债现值
|
| | |
|
13,928,401
|
| | | | $ | 1,961,802 | | |
经营租赁负债 - 流动
|
| | | | 3,524,558 | | | | | | 496,431 | | |
经营性租赁负债 - 非流动
|
| | | | 10,403,843 | | | | | $ | 1,465,371 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
应付工资和社会保险(1)
|
| | | | 57,459,273 | | | | | | 55,943,773 | | | | | $ | 7,879,627 | | |
促销服务费(2)
|
| | | | 64,883,477 | | | | | | 93,688,809 | | | | | | 13,195,979 | | |
所得税以外的税
|
| | | | 1,171,381 | | | | | | 3,005,157 | | | | | | 423,273 | | |
滞纳金(3)
|
| | | | 9,499,595 | | | | | | 9,685,430 | | | | | | 1,364,183 | | |
物业、厂房和设备的应付费用
|
| | | | 48,774,134 | | | | | | 49,128,153 | | | | | | 6,919,653 | | |
疾控中心运存费用
|
| | | | 35,023,095 | | | | | | 48,656,533 | | | | | | 6,853,226 | | |
保证金(4)
|
| | | | 94,528,659 | | | | | | 94,733,524 | | | | | | 13,343,126 | | |
专业服务费(5)
|
| | | | 7,758,448 | | | | | | 2,226,221 | | | | | | 313,561 | | |
其他应付(6)
|
| | | | 7,653,291 | | | | | | 10,215,721 | | | | | | 1,438,874 | | |
合计 | | | | | 326,751,353 | | | | | | 367,283,321 | | | | | $ | 51,731,502 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
工资
|
| | | | 49,020,045 | | | | | | 47,732,121 | | | | | $ | 6,723,023 | | |
社会保障保险
|
| | | | 7,732,161 | | | | | | 7,535,447 | | | | | | 1,061,360 | | |
工会费
|
| | | | 707,067 | | | | | | 676,205 | | | | | | 95,244 | | |
合计 | | | | | 57,459,273 | | | | | | 55,943,773 | | | | | $ | 7,879,627 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
社会保险滞纳金
|
| | | | 9,499,595 | | | | | | 9,685,430 | | | | | | 1,364,183 | | |
合计 | | | | | 9,499,595 | | | | | | 9,685,430 | | | | | $ | 1,364,183 | | |
| | |
系列A
|
| | | | | | | |
系列A-1
|
| | | | | | | |
系列B
|
| |
合计
|
| |
合计
|
| |||||||||||||||||||||
| | |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
携带
值 |
| |
携带
值 |
| ||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||||||||
截至2021年3月31日
|
| | | | 15,534,276 | | | | | | 344,661,893 | | | | | | 6,014,313 | | | | | | 65,665,315 | | | | | | 65,414,858 | | | | | | 875,131,363 | | | | | | 1,285,458,571 | | | | | $ | 181,055,603 | | |
增加到赎回价值
|
| | | | — | | | | | | 28,042,858 | | | | | | — | | | | | | 2,566,412 | | | | | | — | | | | | | 34,404,481 | | | | |
|
65,013,751
|
| | | |
|
9,157,124
|
| |
外币折算
调整 |
| | | | — | | | | | | (4,690,126) | | | | | | — | | | | | | (875,280) | | | | | | — | | | | | | (11,666,321) | | | | |
|
(17,231,727)
|
| | | |
|
(2,427,072)
|
| |
截至2021年9月30日
|
| | | | 15,534,276 | | | | | | 368,014,625 | | | | | | 6,014,313 | | | | | | 67,356,447 | | | | | | 65,414,858 | | | | | | 897,869,523 | | | | | | 1,333,240,595 | | | | | $ | 187,785,655 | | |
截至2022年3月31日
|
| | | | 15,534,276 | | | | | | 389,563,659 | | | | | | 6,014,313 | | | | | | 68,510,809 | | | | | | 65,414,858 | | | | | | 912,146,924 | | | | | | 1,370,221,392 | | | | | $ | 192,994,365 | | |
增加到赎回价值
|
| | | | — | | | | | | 33,793,180 | | | | | | — | | | | | | 2,854,770 | | | | | | — | | | | | | 35,435,288 | | | | |
|
72,083,238
|
| | | |
|
10,152,855
|
| |
外币折算
调整 |
| | | | — | | | | | | 48,011,366 | | | | | | — | | | | | | 8,270,941 | | | | | | — | | | | | | 109,974,790 | | | | |
|
166,257,097
|
| | | |
|
23,417,151
|
| |
截至2022年9月30日
|
| | | | 15,534,276 | | | | | | 471,368,205 | | | | | | 6,014,313 | | | | | | 79,636,520 | | | | | | 65,414,858 | | | | | | 1,057,557,002 | | | | | | 1,608,561,727 | | | | | $ | 226,564,371 | | |
| | |
共享数量
选项 |
| |
平均运动量
每股价格 选项 |
| ||||||
| | | | | | | | |
(人民币)
|
| |||
2021年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
在此期间发放的许可证
|
| | | | — | | | | | | — | | |
在此期间被没收
|
| | | | — | | | | | | — | | |
在此期间进行锻炼
|
| | | | — | | | | | | — | | |
在此期间过期
|
| | | | — | | | | | | — | | |
2022年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
在此期间发放的许可证
|
| | | | — | | | | | | — | | |
在此期间被没收
|
| | | | — | | | | | | — | | |
在此期间进行锻炼
|
| | | | — | | | | | | — | | |
在此期间过期
|
| | | | — | | | | | | — | | |
2022年9月30日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
截至6个月的时间
2022年9月30日 数量: 选项 |
| |
行权价
|
| |
锻炼周期
|
|
| | |
(人民币)
|
| | | |
6,133,005
|
| |
3.4845
|
| |
2021 – 2031
|
|
2,453,049
|
| |
6.4631
|
| |
2021 – 2026
|
|
4,427,368
|
| |
13.1344
|
| |
2021 – 2026
|
|
13,013,422
|
| | | | | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
研发费用
|
| | | | 492,764 | | | | | | (1,015,055) | | | | | $ | (142,970) | | |
一般和行政费用
|
| | | | 2,635,978 | | | | | | 929,739 | | | | | | 130,953 | | |
股票薪酬总额
|
| | | | 3,128,742 | | | | | | (85,316) | | | | | $ | (12,017) | | |
关联方名称
|
| |
与YS集团的关系
|
|
益生生物医药有限公司 | | |
张控制的实体
|
|
益生生物医药控股有限公司 | | |
张控制的实体
|
|
北京亿盛兴业科技有限公司 | | |
张控制的实体
|
|
| | |
截至9月30日的六个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股(香港)有限公司 | | | | | | | | | | | | | | | | | | | |
YS集团代收应收账款
|
| | | | 2,966,777 | | | | | | — | | | | | $ | — | | |
还款给YS集团
|
| | | | 33,055,610 | | | | | | — | | | | | $ | — | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
当期所得税
|
| | | | — | | | | | | — | | | | | $ | — | | |
递延税金
|
| | | | 5,689,586 | | | | | | 565,625 | | | | | | 79,668 | | |
所得税
|
| | | | 5,689,586 | | | | | | 565,625 | | | | | $ | 79,668 | | |
| | |
截至9月30日的六个月
|
| |||||||||
| | |
2021
|
| |
2022
|
| ||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
中华人民共和国法定所得税率
|
| | | | 25.00% | | | | | | 25.00% | | |
不同司法管辖区不同税率的影响
|
| | | | (26.82)% | | | | | | (182.62)% | | |
中华人民共和国优惠税率的效果
|
| | | | 11.98% | | | | | | (100.49)% | | |
研发费用扣除等影响
|
| | | | 30.97% | | | | | | 80.56% | | |
暂时性差异*
|
| | | | 13.42% | | | | | | 5.03% | | |
估值免税额变动
|
| | | | (41.02)% | | | | | | 177.88% | | |
实际税率
|
| | | | 13.53% | | | | | | 5.36% | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
递延税金资产: | | | | | | | | | | | | | | | | | | | |
将存货减记为可变现净值
|
| | | | 825,454 | | | | | | 166,410 | | | | | $ | 23,439 | | |
财产、厂房和建筑物减值
|
| | | | 2,031,460 | | | | | | 1,900,433 | | | | | | 267,674 | | |
延期政府拨款
|
| | | | 4,852,383 | | | | | | 4,680,205 | | | | | | 659,202 | | |
可用于抵销未来应税利润的亏损
|
| | | | 58,257,270 | | | | | | 47,805,830 | | | | | | 6,733,405 | | |
减去:估值免税额
|
| | | | (58,257,270) | | | | | | (47,805,830) | | | | | | (6,733,405) | | |
递延税金资产总额,净额
|
| | | | 7,709,297 | | | | | | 6,747,048 | | | | | | 950,315 | | |
递延纳税义务: | | | | | | | | | | | | | | | | | | | |
因历史收购子公司而产生的公允价值调整
|
| | | | (4,670,213) | | | | | | (4,273,589) | | | | | | (601,931) | | |
递延纳税负债总额
|
| | | | (4,670,213) | | | | | | (4,273,589) | | | | | | (601,931) | | |
递延税金净资产
|
| | | | 3,039,084 | | | | | | 2,473,459 | | | | | $ | 348,384 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
政府对财产、厂房和设备的补助 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 21,847,340 | | | | | | 22,030,690 | | | | | $ | 3,103,001 | | |
添加
|
| | | | 1,552,000 | | | | | | 1,200,000 | | | | | | 169,019 | | |
确认为收入
|
| | | | (1,368,650) | | | | | | (727,839) | | | | | | (102,515) | | |
小计 | | | | | 22,030,690 | | | | | | 22,502,851 | | | | | $ | 3,169,505 | | |
政府用于研发的拨款 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 11,158,551 | | | | | | 10,318,528 | | | | | $ | 1,453,355 | | |
添加
|
| | | | — | | | | | | | | | | | | | | |
确认为收入
|
| | | | (840,023) | | | | | | (8,498,712) | | | | | | (1,197,036) | | |
小计 | | | | | 10,318,528 | | | | | | 1,819,816 | | | | | $ | 256,319 | | |
递延政府拨款总额
|
| | | | 32,349,218 | | | | | | 24,322,667 | | | | | $ | 3,425,824 | | |
少:当前部分
|
| | | | (2,295,701) | | | | | | (3,495,701) | | | | | | (492,366) | | |
非当前部分
|
| | | | 30,053,517 | | | | | | 20,826,966 | | | | | $ | 2,933,458 | | |
| | |
截至9月30日
|
| |||||||||
| | |
2022
|
| |
2022
|
| ||||||
| | |
(人民币)
|
| |
($)
|
| ||||||
疫苗生产设施建设
生命科学办公室 |
| | | | 1,580,000 | | | | | $ | 222,541 | | |
研发
|
| | | | 6,001,375 | | | | | | 845,288 | | |
采购原材料
|
| | | | 20,236,200 | | | | | | 2,850,249 | | |
合计 | | | | | 27,817,575 | | | | | $ | 3,918,078 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
中华人民共和国
|
| | | | 604,094,049 | | | | | | 613,613,563 | | | | | $ | 86,426,880 | | |
其他国家/地区
|
| | | | 26,777,039 | | | | | | 25,068,223 | | | | | $ | 3,530,835 | | |
| | |
3月31日
2022 |
| |
9月30日
2022 |
| |
9月30日
2022 |
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 252,611,535 | | | | | | 3,943,175 | | | | | $ | 555,392 | | |
关联方应付金额
|
| | | | 519,236,876 | | | | | | 848,379,306 | | | | | | 119,493,409 | | |
流动资产总额
|
| | | | 771,848,411 | | | | | | 852,322,481 | | | | | | 120,048,801 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
长期投资,净额
|
| | | | 146,641,652 | | | | | | 164,003,403 | | | | | | 23,099,722 | | |
非流动资产合计
|
| | | | 146,641,652 | | | | | | 164,003,403 | | | | | | 23,099,722 | | |
总资产
|
| | |
|
918,490,063
|
| | | |
|
1,016,325,884
|
| | | | $ | 143,148,523 | | |
负债和权益 | | | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
应计费用和其他负债
|
| | | | 244,082,463 | | | | | | 354,920,428 | | | | | $ | 49,990,201 | | |
应付关联方金额
|
| | | | 3,155,395 | | | | | | 3,528,981 | | | | | | 497,054 | | |
流动负债总额
|
| | | | 247,237,858 | | | | | | 358,449,409 | | | | | | 50,487,255 | | |
总负债
|
| | | | 247,237,858 | | | | | | 358,449,409 | | | | | | 50,487,255 | | |
| | | | | | | | | | | | | | | | | | | |
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;已发行和已发行21,548,589股)
|
| | | | 458,074,468 | | | | | | 551,004,725 | | | | | | 77,608,485 | | |
B系列可赎回可转换优先股(面值
每股价值0.000005美元,100,000,000股 授权;已发行65,414,858股, 未完成) |
| | | | 912,146,924 | | | | | | 1,057,557,002 | | | | | | 148,955,886 | | |
夹层总股本
|
| | | | 1,370,221,392 | | | | | | 1,608,561,727 | | | | | | 226,564,371 | | |
股东亏损: | | | | | | | | | | | | | | | | | | | |
普通股,每股面值0.000005美元,授权股份99,50,000,000股,截至2022年3月31日已发行和已发行股票247,311,533股,截至2022年9月30日已发行和已发行股票246,736,533股
|
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,124 | | |
新增实收资本
|
| | | | 808,502,018 | | | | | | 808,648,509 | | | | | | 113,897,365 | | |
累计亏损
|
| | | | (1,590,567,163) | | | | | | (1,673,775,766) | | | | | | (235,749,706) | | |
累计其他综合收益(亏损)
|
| | | | 83,087,980 | | | | | | (85,565,973) | | | | | | (12,051,886) | | |
股东亏损总额
|
| | | | (698,969,187) | | | | | | (950,685,252) | | | | | | (133,903,103) | | |
总负债、夹层权益和股东亏损
|
| | | | 918,490,063 | | | | | | 1,016,325,884 | | | | |
$
|
143,148,523
|
| |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
子公司股权损失
|
| | | | (27,562,274) | | | | | | (5,703,582) | | | | | $ | (803,346) | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | | | | | | | | | | | | | | | |
一般和行政
|
| | | | 17,037,618 | | | | | | 6,356,204 | | | | | | 895,265 | | |
研发
|
| | | | 492,764 | | | | | | (934,367) | | | | | | (131,605) | | |
总运营费用
|
| | | | 17,530,382 | | | | | | 5,421,837 | | | | | | 763,660 | | |
| | | | | | | | | | | | | | | | | | | |
运营亏损
|
| | | | (45,092,656) | | | | | | (11,125,419) | | | | | | (1,567,006) | | |
其他收入: | | | | | | | | | | | | | | | | | | | |
财务收入,净额
|
| | |
|
1,324
|
| | | |
|
54
|
| | | |
|
8
|
| |
其他收入总额,净额
|
| | | | 1,324 | | | | | | 54 | | | | | | 8 | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (65,013,751) | | | | | | (72,083,238) | | | | | | (10,152,855) | | |
可归因于YS Biophma的净亏损
|
| | | | (110,105,083) | | | | | | (83,208,603) | | | | | | (11,719,853) | | |
| | | | | | | | | | | | | | | | | | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | |
伪造货币兑换收益
|
| | | | 11,321,167 | | | | | | (168,653,952) | | | | | | (23,754,747) | | |
全面亏损
|
| | | | (33,770,165) | | | | | | (179,779,317) | | | | | $ | (25,321,745) | | |
| | | | | | | | | | | | | | | | | | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.18) | | | | | | (0.04) | | | | | $ | (0.01) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
| | | | | | | | | | | | | | | | | | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | $ | (1,566,998) | | |
子公司股权损失
|
| | | | 27,562,274 | | | | | | 5,703,582 | | | | | | 803,346 | | |
基于股份的薪酬
|
| | | | 3,128,741 | | | | | | (85,316) | | | | | | (12,017) | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
关联方应付金额
|
| | | | (298,261,642) | | | | | | (328,910,623) | | | | | | (46,326,745) | | |
应付关联方金额
|
| | | | (42,697) | | | | | | 373,586 | | | | | | 52,619 | | |
应计费用和其他负债
|
| | | | (7,357,523) | | | | | | 55,467,639 | | | | | | 7,812,564 | | |
经营活动中使用的净现金
|
| | | | (320,062,179) | | | | | | (278,576,497) | | | | | | (39,237,231) | | |
汇率对现金的影响
|
| | | | (4,446,303) | | | | | | 29,908,137 | | | | | | 4,212,531 | | |
现金净减少
|
| | | | (324,508,482) | | | | | | (248,668,360) | | | | | | (35,024,700) | | |
期初现金
|
| | | | 330,296,949 | | | | | | 252,611,535 | | | | | | 35,580,092 | | |
期末现金
|
| | | | 5,788,467 | | | | | | 3,943,175 | | | | | $ | 555,392 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 65,013,751 | | | | | | 72,083,238 | | | | | $ | 10,152,855 | | |